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Abstract 
Colorectal carcinoma is one of the leading cancers in Norway. Molecular profiling of the 
different stages of colorectal cancers is still in demand as molecular markers to stratify 
patients for correct treatment response is lacking. This study was carried out to evaluate 
capillary electrophoresis based Sanger sequencing and fragment analysis on the ability to 
detect somatic TP53 mutations in fresh frozen- and formalin fixed and paraffin waxed 
embedded (FFPE) tissue IURP'XNHV¶VWDJH%DQG&colon adenocarcinomas. A small subset 
of samples was also subjected to ion semiconductor sequencing on the Ion Torrent PGMTM ± 
ion semiconductor sequencing. These methods demonstrated that FFPE tissue performed well 
with the fragment analysis assay and on Ion Torrent PGMTM, while the same samples required 
additional purification steps for Sanger sequencing. Sanger sequencing revealed the highest 
number of mutations, and deleted nucleotide composition that were difficult to interpret with 
Sanger sequencing were successfully verified on the Ion Torrent PGMTM. Fragment analysis 
failed to detect all the mutations found by Sanger sequencing. The fragment analysis assay 
can detect mutations at 7 nucleotide positions (SNPs) located in exon 5, 7 and 8, of the TP53 
DNA binding domain. DNA was isolated from 37 surgically removed fresh frozen colon 
tumors and 40 surgically removed FFPE preserved tumors to perform TP53 mutation analysis. 
Univariate, Kaplan-Meier analyses and the log-rank test for TP53 and Dukes¶ stage 
parameters revealed differences in survival amongst 'XNHV¶VWDJHstatus, with no such 
difference for TP53 status. Most mutations were evaluated as inactive mutants, and the 
mutation spectra corresponded well to data published in TP53 databases. The quest for new 
clinically approved biomarkers continues as cancer genome studies reveals an ever growing 
repertoire of mutations previously assumed insignificant in carcinogenesis.  
 
 
 
 
 
 
 
 
 
Sammendrag 
Tykktarms- og endetarms kreft, kolorektal kreft, er en av de hyppigste kreftformene Norge. 
Molekylær profilering av ulike stadier kolorektal kreft er nødvendig da det mangler 
molekylære markører for bedre å stratifisere pasienter til korrekt behandling med gode 
prognoser. Denne studien ble utført for å evaluere to ulike kapillær elektroforese baserte 
metoder, Sanger sekvensering og fragment analyse, ved å undersøke somatiske TP53 
mutasjoner i ferskt frossent- og formalin fiksert og parafin støpt (FFPE) vev fra Dukes' 
stadium B og C tumorer. Et lite utvalg av prøver ble sekvensert på Ion-Torrent PGMTM - ion 
semikonduktor sekvensering. Disse metodene viste at FFPE vev fungerte godt med fragment 
analyse og Ion Torrent PGMTM, mens FFPE prøver krevde ekstra rensetrinn før Sanger 
sekvensering. Sanger sekvensering detekterte flest antall mutasjoner, og DNA sekvenser som 
var vanskelig å lese med Sanger sekvensering ble bekreftet med Ion Torrent PGMTM. 
Fragment analyse metoden inkluderer kun 7 nukleotid posisjoner i kodon 175, 245, 248, 273, 
og 306 i TP53 DNA bindingsdomene og kan derfor detektere få mutasjoner i forhold til 
Sanger sekvensering. DNA ble isolert fra 37 ferske frosne- og 40 FFPE kolorektal svulster for 
TP53 mutasjons analyse. Univariat, Kaplan-Meier analyse og log-rank test for parameterne 
TP53 og Dukes' stadium avdekket forskjeller i overlevelse blant Dukes' stadium, med ingen 
forskjell ble funnet for TP53 status. De fleste mutasjoner ble vurdert til å forårsake et inaktivt 
p53 protein. Distribusjon av mutasjoner stemmer overens med data publisert i TP53 
databaser. Søken etter nye klinisk godkjente biomarkører fortsetter da flere 
sekvenseringsstudier av kreftgenom avslører et stadig voksende repertoar av mutasjoner som 
tidligere er antatt å ha liten betydning for kreftutvikling. 
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1 INTRODUCTION 
1.1 Introduction to Cancer 
Cancer is a heterogeneous and progressive genetic disease that evolves through multiple steps 
of alterations in the genome. There are hundreds of different types of cancers, most of which 
is known to differ in tumorigenesis, histopathology, biological and clinical behavior, as well 
as in treatment response. With such diversity there are some fundamental characteristics all 
cancer cells share in common and must acquire to reach full tumor development and 
malignancy. Through a succession of clonal expansions initiated by genetic alterations a cell 
must; (1) gain a growth advantage and become self-sufficient in growth-stimulating signals; 
(2) evade growth-suppressors to sustain proliferation; (3) gain the ability to invade 
surrounding tissue and metastasize to distant organs; (4) evade replicative cell senescence to 
gain unlimited replication; (5) induce angiogenesis to sustain blood supply/neovasculature; 
(6) evade the apoptotic machinery to resist programmed cell death; (7) alter energy 
metabolism to sustain active proliferation; and (8) evade destruction by the immune system. 
The acquisition of these hallmark characteristics evolves through two enabling hallmarks; (9) 
genome instability and mutations, and epigenetic changes that can trigger the initiation of 
clonal expansion; and (10) inflammations can contribute to the aforementioned characteristics 
and enhance tumorigenesis (Hanahan & Weinberg 2000; Hanahan & Weinberg 2011).  
1.2 Colorectal Carcinoma 
Cancers in the bowel region (bowel, colon, and rectum) are usually referred to as colorectal 
carcinoma (CRC). CRC evolves through well-defined morphological changes in the epithelia 
of the lumen. Colonic lesions or dysplasia can grow and develop into benign adenomatous 
polyps that further grow in size to adenoma. Unless surgically removed, the growing adenoma 
can evolve to malignant invasive carcinoma that may metastasize. Histology from each stage 
of CRC-tumor development alongside molecular characterization serves as a model system 
for multistep carcinogenesis (see section 1.7) (Fearon & Vogelstein 1990; Muto et al. 1975).  
1.3 Epidemiology  
Norway has the highest incidence of cancers in the colon and rectum among men and women 
in the western world. In 2012, 2717 (1294 men; 1423 women) new colon cancer cases was 
registered. The numbers for rectal-, rectosigmoid-, and anal cancers were collectively 1304 
(540 women; 764 men) new cases in 2012. The most common cancer types for both sexes are 
prostate- (men), breast- (women), and lung cancer, including malignant melanoma. Although 
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CRC are most common among women over 70 years of age there is a slight increase in CRC 
among women in general. In men, colon cancer is one of the most common cancers, while 
rectal cancers have stabilized since the 1980s.  
Mortality in 2012 from colon cancer was 1206 (595 women; 611 men), and 298 (181 women; 
217 men) for rectal-, rectosigmoid-, and anal cancer. Prevalence at 5 years after diagnosis is 
5906 for colon-, and 3458 for rectal-, rectosigmoid-, and anal cancer. The relative survival 
rate for colon cancer in 2012 was 60% for men and 63% for women, an increase of about 30% 
since the 1970s. In rectal cancers the relative survival rate in 2012 was 65% for women and 
68% for men. The cumulative risk of developing colon cancer by the age of 75 (2008-2012) 
was 2.8% for women and 3% for men. For rectal-, rectosigmoid-, and anal cancer the 
cumulative risk was 1.3% for women and 2.1% for men (Norwegian Cancer Registry ± 
Cancer in Norway 2012, www.kreftregisteret.no).  
1.4 The Anatomy of the Large Intestine 
The human large intestine (Figure 1A) is about 1.5 meters long and is structurally divided into 
the cecum, colon, rectum, and anal canal. The colonic segments are the ascending-, 
transverse-, descending-, and sigmoid parts, including two bends on each side of the 
transverse colon; the hepatic flexure on the right side, and the splenic flexure on the left side. 
The bowel wall surrounding the lumen of the large intestine is composed of four histological 
layers (Figure 1B); mucosa, submucosa, tunica muscularis, and serosa (peritoneum). Three 
sub-layers constitute the mucosa; a simple columnar epithelium, the lamina propria to support 
 
Figure 1: The large intestine. (A) The locations and sub-sites of the colon and rectum (large 
intestine) (0RVE\¶VPHGLFDOGLFWLRQDU\WKHG6W/RXLV). (B) The tissue layers of the colon 
wall (www.oreilly.com). 
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the epithelium, and the muscularis mucosa; a thin smooth muscular layer external to the 
propria. The submucosa is a layer of highly vascular connective tissue, and the tunica 
muscularis consists of inner circular- and outer longitudinal muscle layers involved in 
peristalsis. The peritoneum of serosa is the outer-most layer and consists of loose connective 
tissue that confines the large intestine. Retro-peritoneal sections without serosa are the 
posterior- ascending and posterior descending colon which are covered in adventitia 
(Yeatman 2013). 
1.5 Histopathology of the Colon ± The Polyp-Cancer Sequence 
The human large intestine is lined with a single layer of epithelial cells that covers the 
invaginated intestinal crypts of the digestive surface (as seen in the first photo of Figure 3). 
The epithelium is renewed every 4-5 days by dividing stem cells that lie protected at the 
bottom of the crypts which generates the four cell types found in the intestinal layer; (1) 
absorptive cells for uptake of nutrients; (2) mucus secreting goblet cells; (3) paneth cells for 
biological defense; and (4) regulatory enteroendocrine cells (Alberts et al. 2008). Most 
colorectal cancers start in the epithelium of the colonic mucosa as microscopic lesions called 
aberrant crypt foci (ACF) (Figure 2). ACF are the first visible signs of alteration in the colon 
and is generally characterized as larger than normal crypts with irregular shape and 
multilayered epithelium. ACF are histologically classified into non-dysplastic, dysplastic, 
hyperplastic, and mixed, each with its own distinct histopathological characteristics (Alrawi et 
al. 2006). ACF are presumed to be precursor (Alrawi et al. 2006) of benign polyps and 
adenomas that subsequently grow into malignant carcinomas according to the polyp-cancer 
sequence (Muto et al. 1975) (Figure 3). Three histological types of benign tumors exists; 
adenomatous polyp (tubular adenoma), villous adenoma (villous papilloma), and an 
intermediate type; tubule-villous adenoma, villo-glandular adenoma or papillary  
Figure 2: Macroscopic and histologic images of ACF 
(red arrows). (a) hyperplastic serrated ACF. (b) serrated 
hyperplastic colonic crypts characterized by stellate-
shaped luminal crypts and a prominent component of 
columnar cells with microvesicular cytoplasm. (c) non-
serrated hyperplastic ACF. (d) non-serrated hyperplastic 
crypts, which are characterized by a lack of crypt 
serration and prominent goblet cells. (a) and (c) are 
endoscopic images of ACF. (b) and (d) are hematoxylin 
and eosin stained images of ACF (Anderson et al. 2010). 
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Figure 3: Polyp-cancer sequence. Histology slides of normal epithelia, adenoma and carcinoma 
according to the polyp-cancer sequence (Cardoso et al. 2007). 
adenoma. Although adenomatous polyps are far more frequent than both villous-adenomas 
and the intermediate types, villous adenomas have a much higher malignant potential. The 
adenomatous polyps (tubular-adenoma) are structurally embedded in the lamina propria as 
branching tubules while villous-adenomas are pointed protrusions of lamina propria covered 
by a layer of epithelia that can be embedded in the muscularis mucosae. The intermediate 
tubulo-villous adenoma can consist of both the tubular and villous structures. The malignant 
potential of colonic polyps generally increases with size and only a fraction of all polyps grow 
large enough to become malignant during a human lifetime (Muto et al. 1975).  
1.6 Oncogenes and Tumor Suppressor Genes 
The malignant transformation of a normal cell is a complex multistep process caused by 
defective genes involved in cell growth, cell division, and cell death. Genetic defects can be 
induced by external chemical and physical agents, intracellular rearrangements, inherited 
germ line or somatic mutations, epigenetic changes and certain viral infections (e.g. Human 
Papillomavirus (HPV), Epstein Barr virus (EBV), and Human Herpesvirus-8 (HHV-8). Two 
distinct functionally and heterogeneous groups of defective genes associated with malignancy 
are the growth-promoting oncogenes and the growth-constraining tumor suppressor genes 
(TSG). Understanding the opposite mechanisms by which these two groups of genes operate 
has been fundamental for unraveling the multistep progress of carcinogenesis (Damania 2007; 
Land et al. 1983; Steele et al. 1998; Weinberg 1994). 
1.6.1 Oncogenes 
In normal cells oncogenes are called proto-oncogenes. Proto-oncogenes encode various 
regulatory proteins (e.g. growth factors, growth factor receptors, signal transducers, and 
nuclear transcription factors) involved in cell growth and cell division (Land et al. 1983; 
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Ramalakshmi & Muthuchelian 2011; Weinberg 1994). Oncogenes are activated through 
mutations in proto-oncogenes leading to amplification of growth-promoting genes whose 
encoded proteins can bypass cell cycle control mechanisms and activate downstream 
transcription (Martin 2004; Weinberg 1994). Mechanisms of activation can be somatic 
mutations (Reddy et al. 1982; Santos et al. 1983; Tabin et al. 1982; Taparowsky et al. 1983), 
gene amplification/gene copy number (Alitalo et al. 1983; Dalla-Favera et al. 1982b; Schwab 
et al. 1983), or chromosomal rearrangements/translocation (Dalla-Favera et al. 1982a; Leder 
et al. 1983; Mushinski et al. 1983). Viral infections can also induce tumorigenesis through 
insertion of oncogenic enhancer elements and promoter sequences to activate proto-
oncogenes (Blair et al. 1981; Conrad & Botchan 1982; DeFeo et al. 1981; Gruss et al. 1981; 
Hayward et al. 1981). Oncogenes are said to be dominant as alteration in only one allele of the 
proto-oncogene is needed to acquire a gain-of-function (Figure 4A) phenotype (Weinberg 
1991).  
For example, somatic mutations in the RAS oncogene family (H-RAS, K-RAS, N-RAS) is 
found in about 30% of all human tumors (Fernandez-Medarde & Santos 2011), with K-RAS 
mutations found in 40-45% of colorectal tumors (Cho & Vogelstein 1992; Fearon & 
Vogelstein 1990; Fernandez-Medarde & Santos 2011). RAS are monomeric GTPases 
involved in signal transduction pathways affecting cell survival, growth, and proliferation. 
GTPases serves as molecular switches that alternates between an active (GTP-bound) and 
inactive (GDP-bound) conformational state. Inactive RAS is anchored to the cytoplasmic 
surface of the plasma membrane where it is activated by surface receptors to relay signals to 
downstream effector proteins. Upstream signals induce RAS guanine nucleotide exchange 
factors (RAS-GEFs) to activate RAS by dissociation of GDP, thereby affiliating the uptake of 
cytosolic GTP. Inactivation is induced by RAS GTPase-activating proteins (RAS-GAPs) that 
catalyzes RAS to hydrolyze its bound GTP to GDP (Malumbres & Barbacid 2003). Mutations 
in RAS is confined to residue 12 (Gly12) and 61 (Gln61) which obstruct its binding capacities 
to GAP and consequently affects GTP hydrolysis, leaving a constant flow of growth-
promoting signals to activate downstream effectors that can promote tumorigenesis 
(Malumbres & Barbacid 2003; Reddy et al. 1982; Santos et al. 1983; Taparowsky et al. 1983).  
1.6.2 Tumor Suppressor Genes 
TSGs encode regulatory proteins involved in suppressing cell growth and proliferation, as to 
maintain cell- and tissue architecture through pathways like, cell cycle check-points, DNA 
repair mechanisms, senescence and apoptosis. Mutant inactive or lost (deleted) TSG protein 
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products lose their maintenance ability, and liberate the cell, by definition, to continue to grow 
and proliferate to neoplastic growth (Weinberg 1991). Mechanisms of TSG inactivation are 
inherited and somatic mutations (Knudson 1971), usually followed by chromosomal 
rearrangements and deletions (Baker et al. 1989; Dong 2001) leading to loss of heterozygosity 
(Kanazawa et al. 2002). Epigenetic changes can also silence TSGs through DNA methylation 
(Jones & Laird 1999). Viral infections induce tumorigenesis by inactivating TSGs through 
onco-proteins that target and form complexes wiWK76*VSURWHLQGRPDLQV³SRFNHWV´
necessary for normal binding properties (Helt & Galloway 2003; Hu et al. 1990; Münger et al. 
2004; Weinberg 1995). Unlike oncogenes, TSGs are recessive as alteration in both alleles of 
the gene is necessary for a loss-of-function (Figure 4B), known as the two-hit hypothesis 
(Knudson 1971; Weinberg 1991). The two-hit hypothesis was first attributed to the childhood 
cancer retinoblastoma where Knudson, 1971, reported that children with retinoblastoma had a 
dominantly inherited form with one germline mutation and that a second mutation had 
occured in somatic cells. Adults affected with retinoblastoma had a non-hereditary form 
where both mutations occurred in somatic cells. It is now clear that retinoblastoma is caused 
by mutations in both alleles of the retinoblastoma gene, RB1. pRB is involved in cell cycle 
regulation where it acts as a suppressor for transcription factors of the E2F family. 
Phosphorylation of pRB realeses E2F and leads to S-phase entry and replication in the cell 
cycle (Burke et al. 2012; Nevins 2001). However, TSGs can also show oncogenic behavior 
through a dominant-negative effect in which, for example, mutant p53 protein can dimerize 
with wild-type (wt) p53 dimers and inactivate otherwise functional p53 tetramers (Fearon & 
Vogelstein 1990). 
 
Figure 4: Dominant and recessive mutations in oncogenesis. Solid red boxes represents activating 
mutations, hollow red boxes represents inactivating mutations. (A) Dominant; a gain-of-function 
mutation in a single allele of oncogenes can drive tumor formation. (B) Recessive; a loss-of function 
in both alleles of tumor suppressor genes are necessary to drive tumor formation (Alberts et al. 2008) 
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1.7 Genetic Model of Colorectal Carcinoma - The Adenoma-Carcinoma Sequence 
The adenoma-carcinoma sequence was first proposed by Fearon and Vogelstein in 1990 as a 
multistep genetic model for the development of colorectal carcinoma (Figure 5). The 
transition from normal epithelia to benign adenomas and malignant carcinomas involves the 
accumulation of genetic alterations in oncogenes (KRAS) and TSGs (APC, DCC, TP53).  
 
 
Figure 5: The adenoma-carcinoma sequence. Genetic model of tumor formation - from normal 
epithelium to carcinoma - involves the inactivation of TSGs and activation of oncogenes initiated 
through CIN or MIN (Fauci et al. 2008). 
In 2012, The Cancer Genome Atlas (TCGA) project identified a total of 32 mutated somatic 
genes in colon and rectal cancers, and it is now recognized that CRC evolves through three 
main pathways; the chromosomal instability (CIN) pathway, the microsatellite instability 
(MSI) pathway, and through epigenetic mechanisms. CIN is characterized by loss or gain of 
whole chromosomes or chromosomal regions leading to aneuploidy, and is found in 
approximately 70-80% of CRC cases. MIN is insertions or deletions of short repetitive DNA 
segments (microsatellites) of 2-5 nucleotide bases and is associated with defective mismatch 
repair (MMR) genes observed in 15% of CRC cases. Epigenetic changes like promoter 
methylation of CpG (cytosine-phosphate-guanine) islands (CIMP) is a distinct phenotype in 
CRC associated with MIN (Cardoso et al. 2007; Kawasaki et al. 2008; TCGA 2012). 
Oncogenic pathways have distinct genetic characteristics, but in general, early events in 
carcinogenesis involves gain/loss of DNA methylation which may result in CIN followed by 
aneuploidy, and MIN and LOH in TSGs on chromosome 5q (APC), 17p (TP53), and 18q 
(DCC), and oncogenes on 12p (KRAS). Deletion of 5q and RAS mutations occurs in early 
stage adenomas while loss of 17p and 18q are events in late adenomas and carcinomas 
(Fearon & Vogelstein 1990). Less than 10% of CRCs have been shown to harbor mutations in 
all 3-4 genes mentioned here which are evident of multiple pathways to CRC, however, the 
inactivation of APC is considered the first event in CRC-development found in more than 
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80% CRC-cases. The transition from adenoma to carcinoma is associated with loss of 17p 
(TP53) in 75% of CRC and in several other cancers. Amplification and rearrangements are 
not common events in CRC (Bodmer 2006; Fearon & Vogelstein 1990). 
APC mutations found in dysplastic ACF is associated with malignant carcinoma, while e.g. 
KRAS2 mutations found in heteroplastic ACF is associated with benign adenomas (Cardoso 
et al. 2007).  
1.8 Cellular Pathways in Colorectal Cancer 
Altered gene expression deregulates multiple cellular signaling pathways during tumor 
progression. Common pathways found altered in CRC are the Wnt, 7*)ȕMAPK, PI3K and 
p53 pathways (Figure 6) (TCGA 2012). The Wnt (Wingless) SDWKZD\UHJXODWHVȕ-catenin, a 
signal transducer leading to transcriptional activation of several critical cancer genes (TCF-1, 
Myc and, CCND1), but Wnt signaling also sustain the proliferation of stem cells in the 
intestinal crypts before they migrate to differentiate. The APC protein is a crucial component 
of the Wnt signaling pathway as a major element of a degradation complex consisting of 
APC, Axin and glycogen synthase kinase (GSK3ȕ In the absence of a Wnt signal the APC-
complex ubiquinate ȕ-catenin for degradation in the proteasome and no transcription is 
activated. In the presence of a Wnt signal, the APC-complex is disengaged leaving ȕ-catenin 
 
Figure 6: Cellular pathways in colorectal cancer. Genes in red are affected in several common 
pathways during colorectal cancer development (www.genome.jp (hsa05210)). 
9 
 
to accumulate and translocate to the nucleus where it stimulates transcription (Ougolkov et al. 
2004). During tumorigenesis the Wnt pathway is thus activated by inactive APC rather than 
the normal cascade from extracellular ligands.    
1.9 TP53 ± Tumor Suppressor Protein p53  
p53 is a nuclear protein and a transcription factor found at basal levels in normal cells. In 
response to a wide range of stress factors (e.g. metabolic changes, nucleotide pool depletion, 
DNA damage, telomere erosion, hypoxia, UV and ionizing radiation, oncogene activation, 
nutrient and oxygen deprivation, and heat shock) p53 can respond to help the cell repair 
damages and survive, or, in more severe cases, it can induces either cell cycle arrest, 
apoptosis, or senescence (Figure 7) (Burns & El-Deiry 1999; Gottlieb & Vousden 2010). 
 
Figure 7: p53 signaling pathways. Stress signals induce p53 activation through 
several mechanisms leading to an array of cellular responses (www.genome.jp (hsa04115)). 
The TP53 gene is one of the most studied and frequently mutated gene in human cancers 
(Olivier et al. 2010). Located on the short arm of chromosome 17 (17p13) (Figure 8) 
(Benchimol et al. 1985; McBride et al. 1986) TP53 is 20 kb long composed of 11 exons, of  
 
Figure 8: Chromosome 17. TP53 is located on the short arm p13.1 indicated by the 
red line (www.genecards.org). 
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which exon 1 is non-coding followed by a 10 kb intron (Figure 9A) (Lamb & Crawford 1986) 
TP53 encode a 393 amino acid long (Harlow et al. 1985), 53 kDa (Crawford et al. 1981; Lane 
& Crawford 1979) tumor suppressor protein, p53 (Finlay et al. 1989). 
1.9.1 p53 Structure 
Cellular p53 is a tetramer (dimer of dimer) of four subunits (Figure 9B) (Chen et al. 2010). 
Each subunit can be divided into 5 domains with distinct functions, and it contain 5 
evolutionary highly conserved domains (HCD) (Hjortsberg et al. 2008); (1) The amino-
terminus (N-terminus) (1-42) contains the acidic transactivation domain, the Mdm2 protein 
binding site, and the HCD I (Brady & Attardi 2010; Burns & El-Deiry 1999); (2) A proline 
rich domain (40-92) that contain a second transactivation domain involved in apoptotic 
activation (Venot et al. 1998); (3) The core DNA binding domain (101-306) for sequence-
specific binding to response elements. It contains the HCD II to V, and it is the domain in 
which 90% of p53 mutations are found (Hjortsberg et al. 2008); (4) A tetramerization domain 
(307-355) that FRQVLVWRIDȕ-VWUDQGDQGDQĮ-helix for quaternary stabilization, including a 
nuclear export signal (NES) (Joerger & Fersht 2010); (5) The carboxy-terminus (C-terminus) 
(356-393) regulatory domain (CAD) includes 3 nuclear localization signals (NLS) and a 
second NES, and is involved in non-sequence-specific binding to the promoter TATA-
element to supress many target genes (Coutts et al. 2009; Seto et al. 1992). Both the amino- 
and carboxy-terminus are sites subjected to numerous post translational modifications (e.g. 
phosphorylation, acetylation, ubiquitination, sumoylation, and neddylation) to modulate p53 
activity and localization during homeostasis and stress-induced responses (Kruse & Gu 2009). 
  
Figure 9: TP53 domains and structure. (A) Exon boundaries with codon numbers and functional 
domains of the TP53 gene (www.stjude.org). (B) Crystal structure (3KMD.pdb) of a self-assembled 
p53 tetramer with its core domain bound to a full consensus site in the DNA strand (www.pdb.org). 
 
A                        B 
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1.9.2 p53 Regulation 
The transcriptional activity of p53 is kept under tight control in unstressed cells through 
Mdm2-mediated proteasomal degradation. Mdm2 binds to the p53 N-terminal region and 
undergoes a conformational change tRILWD³XELTXLWLQDWLRQVLJQDO´located in the core DNA 
binding domain in p53 to poly-ubiquinate and target p53 for 26s proteasomal degradation. 
p53 can either be degraded in the cytoplasm, or in the nucleus during down-regulation when 
rapid decrease in p53 transcriptional activity is necessary. Mdm2 also mediates p53 nuclear 
export by mono-ubiquitinate lysine residues in the C-terminal region and the core DNA 
binding domain in p53 which exposes the p53 C-terminal NES, leading to its nuclear export. 
Stable mono-ubiquitinated p53 proteins have been found translocated to control 
mitochondria-directed apoptosis, and are thought to have other, yet unknown, cytoplasmic 
functions.  
The transcriptional activation of Mdm2 is regulated by p53. In this way, p53 is regulated in a 
negative autoregulatory feedback-loop where poly-ubiquitination and degradation of p53 
occurs during high Mdm2 levels, and activity directed mono-ubiquitination of p53 occurs 
during low Mdm2 levels. (Coutts et al. 2009; Kubbutat et al. 1997; Moll & Petrenko 2003).  
1.9.3 p53 Activation 
p53 is activated through three independent pathways; (1) in response to DNA damage p53 is 
phosphorylated by the protein kinases ATM, ATR, Chk1 and Chk2; (2) oncogene activation 
of Ras or Myc triggers aberrant growth signals to stimulate p14ARF protein to activate p53; 
and (3) chemical agents, radiation, and protein-kinase inhibitors triggers p53 phosphorylation 
by ATR and casein kinase II. Upon p53 activation, p53 degradation ceases, allowing p53 to 
carry out its transcriptional activation on target genes that ultimately leads to either cell-cycle 
arrest, apoptosis, or senescence (Vogelstein et al. 2000).     
1.9.4 p53 in Cell-Cycle Control 
During the cell cycle a cell grows and divides into two daughter cells. The cell cycle involves 
the interphase and mitosis. The interphase consists of Gap 1 (G1), Synthesis (S), and Gap 2 
(G2), and the mitotic (M) phase consists of prophase, metaphase, anaphase, and telophase, and 
cytokinesis (Figure 10). During the G1 phase the cell grows in size before entering the S phase 
for chromosome duplication, and then exceeds to the G2 phase for further growth and 
preparation for mitosis. In the mitotic phase the sister chromatids are disassembled and 
distributed in two daughter cells (cytokinesis).  
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Figure 10: Cell cycle control system. Cell cycle starts in G1. Each gap in the circle represents a major 
checkpoint controlled by the different cyclin dependent kinases and their cyclins 
(http://www.abcam.com). 
The cell cycle is tightly regulated by the cell-cycle control system, mainly the cyclin-
dependent kinases (Cdks) and their associated cyclins, at three major check-points positioned 
at the transition from G1 to S, G2 to M, and from metaphase to anaphase. Progression through 
each of these checkpoints is blocked in response to any complications that might cause 
damage in the duplicated cells, and cell cycle arrest occurs until the problem is fixed and the 
cell can proceed to the next phase. In response to DNA damage during the cell cycle, p53 is 
phosphorylated by kinases such as DNA-dependent kinase, ATM, Chk1 and Chk2, to mediate 
p21WAF1/CIP1 expression. p21WAF1/CIP1 is a negative regulator of Cdks responsible for G1/S and 
G2/M transition (Vogelstein et al. 2000). To sustain G1 arrest, p53 mediated expression of p21 
inhibits cyclin D/cdk4 and cyclin E/cdk2 kinase activity required for G1/S transition. 
Normally, the G1 cyclin/Cdks regulate the G1/S transitional cyclins through the E2F 
transcription factor. E2F is repressed by pRb which dissociates E2F upon phosphorylation by 
G1 cyclin/Cdks which promotes E2F transcription of cyclins required during S-phase (el-
Deiry 1998; Helton & Chen 2007; Hiyama et al. 1998).  
During S-phase there are two internal check-points to ensure correct replication of 
chromosomes. The intra-S check-point is activated in response to DNA damage, and the 
replication check-point prevents collapse of the replication fork on DNA polymerase during 
DNA damage repair. p53 is, however, not associated with S-phase arrest, instead p53 is 
redirected to promote DNA repair mechanisms, although there are indications that a p53 
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isoform, ǻp53, might be involved in intra-S arrest by activating p21 and 14-3-3ı(Helton & 
Chen 2007). The G2/M check-point prevents the segregation of damaged chromosomes during 
mitosis. In the event of G2/M arrest, p53 mediates p21 expression to inhibit cyclin B/Cdk1 
activity required for M-phase entry. p53 also mediates the expression of other proteins to 
sustain G2 arrest, such as 14-3-ı*$''B99, and Reprimo. The expression of 14-3-ı
can direct cyclin B/Cdk1 out of the nucleus to sustain G2 arrest (el-Deiry 1998; Helton & 
Chen 2007; Vogelstein et al. 2000).    
1.9.5 p53 Mediated Apoptosis  
Apoptosis is a way of eliminating damaged or oncogenic cells from tissues by programmed 
cell death. p53 induces apoptosis through a proteolytic cascade of caspases within the intrinsic 
mitochondrial and the extrinsic death receptor pathway. The intrinsic pathway is activated 
through ATM, ATR, Chk1, or Chk2 phosphorylation of p53 in response to damaging stimuli. 
Phosphorylated p53 induces transcription of pro-apoptotic BH3-only proteins within the Bcl-2 
family, like Bax, Noxa, and Puma, and can repress transcription of anti-apoptotic genes like 
Bcl-2, including the inhibitor of apoptosis gene, Survivin. Upregulation of Bax, Noxa or Puma 
triggers the release of cytochrome c from the mitochondria, which binds to Apaf-1. Apaf-1 
oligomerizes to form the apoptsome which recruit and activate initiator caspases. Activated 
caspases, in turn, activates downstream effector caspases of the proteolytic cascade that lead 
to cell death. A second approach is seen in p53-dependent PIG activation where PIG produces 
reactive oxygen species to induce cytochrome c release from the mitochondrion to trigger the 
proteolytic cascade.  
The extrinsic death receptor pathway relies on tumor necrosis factor (TNF) receptors that 
contain a death receptor domain to bind incoming FasL and TRAIL (Tumor Necrosis Factor-
related apoptosis-inducing ligand) ligands. FasL ligand binds to Fas/APO1 receptor or a 
decoy FAS receptor. Activation of Fas/APO1 recruits the adaptor protein FADD to initiate the 
formation of the death-inducing signaling complex (DISC) and recruit initiator caspases to be 
activated in the DISC. Activated caspases then activates effector caspases to induce cell death. 
The TRAIL receptors, KILLER/DR5 and DR4, and the decoy receptors TRID and TRUNDD, 
triggers a caspase cascade through adaptor proteins and initiator caspases that results in cell 
death. p53 can induce transcription of all four TRAIL receptors, although the most common 
p53-dependent apoptosis is through the intrinsic pathway (Amaral et al. 2010; Burns & El-
Deiry 1999). 
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1.9.6 p53 in Senescence 
Cellular senescence is also a way of eliminating damaged or oncogenic cells from tissue, 
except senescent cells does not undergo programmed cell death. Senescent cells appear to 
exhibit enlarged and flattened morphology and are characterized by a permanent, irreversible 
state of growth arrest without the ability to synthesize DNA or proliferate, while still 
maintaining active metabolism. Telomere shortening, DNA damage, oncogenic stimuli and 
tumor suppressive activity, or chromatin remodeling, can activate senescence in which p53 
acts as a critical regulator in response to senescence biomarkers SA-ȕ-Gal and SAHF 
(Senescence-Associated Heterochromatic Foci), with the ability to promote expression of p21, 
PML plasminogen activator inhibitor (PAI-1), and DEC1, which also accounts as senescence 
biomarkers. Many p53 isoforms and the p53 homologs p63 and p73 are implicated in cellular 
senescence (Itahana et al. 2001; Qian & Chen 2013). 
1.10 TP53 Mutations 
While p53 plays an important role in regulating normal cell growth, the TP53 gene is 
frequently mutated in human cancers, leading to a truncated or inactive p53 protein function. 
About 3.600 publications have reported more than 35.000 TP53 mutations within numerous 
tumor types and cell lines (Figure 11). Currently there are two curated databases for TP53 
mutations, IARC TP53 Database (R16, November 2012) and Universal Mutation Database 
p53 (UMD-p53) (R1, June 2012). Both databases compile the occurrence of somatic 
mutations, germ line mutations, functional data on mutant proteins and TP53 gene status of 
 
Figure 11: Trends in TP53 analysis. (A) Represents published mutations detected by Sanger 
methodology (red) or NGS (blue) pr. year. (B) Novel mutations registered pr. year. (C) Distribution of 
p53 mutations in different cancers worldwide. (D) Common mutational events found in CRC (Leroy et 
al. 2013). 
   C                   D 
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cell-lines. The UMD-p53 database provides several datasets, user friendly analytical tools to 
manage p53 mutations and generate ready-to-use tables with information on each TP53 
mutation status, including software to analyze newly discovered TP53 mutants ± making this 
an interesting website to conduct research on TP53 mutations. However, when interpreting 
TP53 mutations, one must be cautious of the heterogeneity within the observed variety for 
specific loci (especially codon 175, 248, and 273), differences in frequency between tumor 
types, and the mutant effect on biological properties. Several hot-spot mutations (codon 175, 
245, 248, 273, 282) found within the DNA binding domain is connected to key residues 
necessary for protein-protein interactions of p53 target genes. 
More than 70% of TP53 mutations are missense mutations found outside hot-spot regions, 
while roughly 30% accounts for rare variants listed only 1-3 times. Such rare variants were 
possibly generated from artifacts in PCR and sequencing errors, typing errors and incorrect 
codon assignment, and it is estimated that 2-5% of TP53 mutations listed in the database are 
incorrect.  
TP53 mutations exhibit distinct features in various cancers. The majority of mutations found 
in CRC patients are GC>AT transitions at CpG dinucleotides, while in lung cancer it is 
GC>TA transversions (Figure 11D). Tandem mutations in skin cancer are also linked to UV-
exposure, something rarely seen in internal tumors.  
TP53 contains 42 CpG dinucleotides frequently mutated. The mutational effect of CpG 
dinucleotides should be evaluated in detail as they can generate different mechanism 
depending on the residue affected in the coding sequence. These CpG sites can occur in 3 
forms; CGN (type I), NCG (type II), or NNC GNN (type III). A transition at C or G in type I 
lead to amino acid substitution. In type II, only transition at the C residue will lead to an 
amino acid substitution. Due to the degeneration of the genetic code, transition at type II G 
residue has no effect, which is also the case for type III C residue. In type III, only transition 
at G will lead to an amino acid substitution (Hjortsberg et al., Leroy et al., 2013, Soussi and 
Beroud, 2003).  
10.10.1 p53 Functional Categories  
According to their in vitro transactivation ability towards eight transcription promoters in 
yeast, p53 mutations have been classified as active or inactive depending on the location of 
WKHDIIHFWHGUHVLGXHLQWKHSURWHLQHJFRUHGRPDLQ1+GRPDLQ&22+GRPDLQĮKHOL[
DQGȕVWUDQGHWF(Iacopetta et al. 2006; Kato et al. 2003; Soussi et al. 2005). By evaluating 
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the clinical significance of ~3000 TP53 mutations registered in the UMD-p53 database, 
Iacopetta et al. IRXQGWKDWRQO\&5&SDWLHQWVZLWK'XNHV¶VWDJH'WXPRUVZHUH
associated with significantly worse outcome when having inactive TP53 mutations, while no 
such significance could be found for DukeV¶VWDJH$-C. As the mutation repertoire of tumor 
suppressor genes, such as TP53 in the IARC database (http://p53.iarc.fr/) and UMD_p53 
database (http://p53.fr/) is growing, the identification of new genetic markers is important for 
new drug development and to aid oncologists to the best suited treatment for their patients. 
1.11 Clinical Characteristics of Colorectal Cancer 
1.11.1 Staging  
Staging of CRC is based on The TNM (Tumor extent, lymph Node status, Metastases status) 
Staging System, but are also trDGLWLRQDOO\FODVVLILHGDV'XNHV¶VWDJH$-D (Table 1). These 
systems rely on the morphological and histopathological characteristics of the tumor, and the 
extent of penetration of the tumor through the histological layers of the bowel wall (Figure 
12A). Tumor grade describes how quickly the cancer is growing and is determined from the 
extent of cell differentiation defined as low, moderate (Figure 12B), or high. The malignant 
character (tumor stage) is defined by the ability of the neoplastic cells to invade the 
surrounding tissue layers (Figure 12C), and a full malignant cancerous phenotype is fulfilled 
through the ability to metastasize to distant organs.  
 
       
 
Figure 12: Tumor stage and grade. (A) Penetration of the tumor in to the bowel wall here 
represented by TNM staging (https://visualsonline.cancer.gov). (B) Moderately differentiated 
adenocarcinoma. (C) Tumor has grown through the wall and into the adipose layer (black arrow) 
(courtesy of pathologist Solveig Norheim Andersen, Dept. Pathology, Ahus). 
About 85% of CRCs are moderately differentiated and the histology of Dukes stage B and C 
tumors is very similar. Metastases to distant organs can be either through lymph nodes or 
A                                                                   B            C 
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through veins. Metastases through veins lead directly to liver metastases, and are usually more 
aggressive than metastases to lymph nodes (Compton & Greene 2004). 
Table 1: 'HILQLWLRQRI'XNHV¶VWDJH$-D, TNM stage, and TNM classification.  
'XNHV¶VWDJH 'XNHV¶GHILQLWLRQ TNM stage TNM classification 
A Tumor confined to the muscularis propria  I T1,T2; N0; M0 
B Tumor penetrates the muscularis propria IIA T3; N0; M0 
IIB T4; N0; M0 
C Metastases to lymph nodes IIIA T1, T2; N1; M0 
IIIB T3, T4; N1; M0 
IIIC Any T; N2; M0 
D Local or distant metastases IV Any T; Any N; M1 
Table adapted from (Compton & Greene 2004; Dahl 2007). For detailed description on TNM classification see 
(Compton & Greene 2004). 
 
1.11.2 Prognosis 
For patients operated for CRC, the prognosis is dependent on cancer stage at the operation 
time and patients operated for 'XNHV¶A have best prognosis, while the prognosis is worse for 
'XNHV¶C patients. The most challenging group of patients belongs to 'XNHV¶group B patients 
where 5 years cancer specific survival varies between 75% and 90%. It is debated if some of 
the 'XNHV¶B tumors may actually be 'XNHV¶C (metastases to regional lymph nodes), and 
therefore should be offered adjuvant chemotherapy to improve survival (Dahl 2007). There 
are also genetic pin-points that left- and right sided colon cancer and rectum cancer differs in 
pathogeneses, and show different treatment response (Yamauchi et al. 2012).  
1.11.3 Treatment Strategies  
The specific treatment strategy is different for primary, advanced, or metastatic CRC, and 
depends on the type and stage of CRC based on available clinicopathological characteristics. 
Common chemotherapeutic drugs used in treating CRC is 5-fluorouracil (5-FU) alone or in 
combination with leucovorin to increase the effect of 5-FU, capecitabine (5-FU pill form), 
irinotecan, and oxaliplatin, in addition to monoclonal antibodies (mAb) for targeted therapy 
which include bevacizumab, cetuximab, and panitumumab (Winder & Lenz 2010). While 
many surviving patients suffer from recurring tumor growth, the mechanisms behind 
cytotoxic chemotherapy and anti-cancer drugs that cause cardiotoxicity also needs further 
elucidation (Raschi et al. 2010).  
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1.11.4 Prognostic and Predictive Markers 
KRAS is the most common biomarker used by clinicians in metastatic CRC patients. 
Metastatic CRC patients with KRAS mutations do not respond to mAbs cetuximab when 
combined with oxaliplatin, and the addition of cetuximab can even have harmful side effects 
in some patients. However, the majority of metastatic CRC patients with wt-KRAS given 
cetuximab and FOLFIRI (leucovorin/5-FU/irinotecan combined) show improved response 
rate and progression free survival. Metastatic CRC patients with wt-KRAS are thus 
recommended to be treated with mAb panitumumab and cetuximab, and it is becoming a 
common practice to genotype metastatic CRC patients for KRAS mutations to determine 
treatment outcome.  
Patients with wt-BRAF also show improved progression free- and overall survival over 
patients with BRAF mutations when treated with chemotherapy combined with cetuximab, 
although, BRAF status is not currently offered as a standard test to be used in treatment 
outcome (Kulendran et al. 2011).  
Genetic alterations and several candidate genes show potential as molecular markers (e.g. 
18qLOH, TP53, SMAD4, VEGF, EGFR, TS, DPD, ERCC1, PIK3CA; for a more detailed 
review see Winder and Lenz (2010) and Kulendran (2011)) but, there are conflicting results at 
such a detailed level where the difference in treatment and survival can be ruled down to a 
specific base substitution in a single allele (Kulendran et al. 2011; Winder & Lenz 2010). 
Patients with MSI tumors also show better prognosis than patients with CIN tumors, and 
when not subjected to adjuvant chemotherapy, MSI-H tumors show better prognosis than 
MSI-L tumors in resected stage II and III CRCs (Kulendran et al. 2011). Currently, only two 
molecular markers are available; MSI as an established prognostic marker, and KRAS 
mutations as an established predictor of anti-EGFR-targeted treatment with cetuximab or 
panitumumab (Winder & Lenz 2010). The existing histopathological characteristic is not 
enough to stratify patients with CRC, and there is lack of markers which can be used in 
selecting patients with 'XNHV¶B tumors that could benefit from adjuvant chemotherapy (Dahl 
2007; Kulendran et al. 2011). 
1.12 Mutation Detection Methods 
There are numerous techniques for detecting genetic alterations using sequence-, 
hybridization-, or cleavage-based methods depending on what kind of mutations are surveyed, 
whether at chromosome or nucleic acid level, or whether to determine chromosomal 
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rearrangement, chromosomal translocation, insertions and deletions, or point mutations. Only 
sequenced based methods have been employed in this study, and our theoretic focus will 
therefore be on sequence based technology. 
1.12.1 DNA Sequencing Technology 
There has been an enormous development in the field of DNA sequencing techniques only in 
the last 5 years. Since The Sanger method HPHUJHGLQWKH¶V, DNA sequencing technologies 
has been classified as first, second, and now, third- or next generation sequencing (NGS). 
NGS is a common term used for a new line of technologies utilizing semiconductor-, 
microfluidics- and nanotechnology to achieve higher throughput, faster turnaround, length of 
reads, and consensus accuracy. Examples of NGS platforms include 454 GS Junior (Roche), 
MiSeq (Illumina) and Ion Torrent PGM (Life Technologies). DNA sequencing is now widely 
used in clinical applications, system- and comparative biology, epidemiology, for whole 
genome sequencing, including many other disciplines. These new emerging technologies are 
so advanced that the sequencing discipline is entering a new dimension with the possibilities 
to determine a wide range of biological mechanisms. Applications available for NGS makes it 
possible to sequencing a genome in just a few days, determine sites of DNA methylation on a 
genome-wide scale, monitor active regulatory chromatin depletion and histone-bound DNA 
activity, protein-DNA interactions, three-dimensional genome structure, and parallel analysis 
of RNA structure, just to mention a few as there are dozens of other available applications to 
choose from (Shendure & Aiden 2012). 
1.12.2 First Generation Sequencing 
Two prominent DNA sequencing techniques emerged in the 19¶VWKHHQ]\PDWLFGLGHR[\
chain-termination method developed by Sanger et al. (1977), and the chemical degradation 
method developed by Maxam and Gilbert (1977). As technology developed the Sanger 
method was better suited for automation due to the need of fewer toxic chemicals and less 
radioactive isotopes than the Maxam-Gilbert method. The introduction of polymerase chain 
reaction (PCR), cycle sequencing with fluorescent dyes, and capillary electrophoresis made 
the Sanger sequencing the method of choice, a position it still holds today, as the gold 
standard procedure for sequencing long read fragments (Schadt et al. 2010).   
1.12.3 Sanger Dideoxy Sequencing 
The Sanger Dideoxy Sequencing technique, also known as the dideoxy-mediated chain-
termination method Sanger et al. (1977), used the principle of DNA replication in which DNA 
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polymerase can incorporate nucleoside analog to the deoxynucleoside triphosphate (dNTP); 
2´, 3´- dideoxynucleoside triphosphate (ddNTP) that lack the hydroxyl group (-OH) on the 3´- 
carbon of the sugar, preventing phosphodiester bridge formation with the 5´-phosphate of the 
succeeding dNTP (Figure 13). 
Essential components for Sanger sequencing requires a single- stranded DNA template 
(ssDNA), a sequencing primer, DNA polymerase (without exonuclease activity), 
deoxynucleotides (dNTPs; dA, dT, dC, dG), dideoxy-nucleotides (ddNTPs; ddA, ddT, ddC, 
ddG), and reaction buffer.Traditionally, either radioactive (32P, 33P, 35S) internal labeled dATP 
or 5´32P-labeled primers were used in four separate reactions, each containing all four dNTPs 
(dA, dT, dC, dG) and a small amount of one of the four ddNTP (ddA, ddT, ddC, ddG). DNA 
polymerase randomly incorporates either a dNTP or ddNTP to the 3´-end of the newly 
synthesized strand. Incorporation of a ddNTP that lack the -OH group prevents 
 
Figure 13: Nucleoside analogs. NTP, dNTP, and ddNTP, are phosphate-sugar nucleoside analogs. 
DNA synthesis continues with the incorporation of a dNTP. Incorporation of ddNTP terminates DNA 
synthesis (www3.appliedbiosystems.com). 
phosphodiester bridge formation with the 5´-phosphate of the succeeding dNTP, which 
terminates synthesis in a base-specific manner at each nucleotide position of the synthesized 
strand. Each reaction of DNA fragments were then separated in adjacent lanes through 
denaturing polyacrylamide slab gel electrophoresis, and resolved on an autoradiograph to 
detect the radioactive bands. The DNA sequence were manually read in the 5´-3´ direction 
from the bottom of the gel and upwards (www3.appliedbiosystems.com).  
1.12.4 Automated Cycle Sequencing 
Modern automated cycle sequencing follows the principle of Sanger sequencing and requires 
the same essential components like ssDNA template, a sequencing primer, thermostable DNA 
polymerase (without exonuclease activity), dNTPs, ddNTPs, and reaction buffer. The 
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extension products are labeled with four different fluorescent dyes rather than radioactive 
dyes, either by dye-labeled ddNTPs (dye terminators) or 5`-dye-labeled primers (dye 
primers). Dye terminators and the essential sequencing components are combined in one 
single reaction. Dye primers are processed in four separate reactions. The extension products 
are amplified through cycles of annealing, extension, and denaturation on a thermal cycler, to 
produce DNA fragments that are terminated in a base-specific manner by one of the four dye-
labeled ddNTPs. Each fragment is separated through automated capillary electrophoresis and 
the 3`-terminal ddNTP are resolved from the different wavelength each of the four fluorescent 
dyes emits when excited by light. The DNA sequence is then converted to digital data and 
resolved as an electopherogram (www3.appliedbiosystems.com). 
1.12.5 Capillary Electrophoresis 
Automated sequencing machines with capillary array electrophoresis (CE) made injection, 
separation, and optical detection of biological substances possible in a high-throughput 
fashion. In this study we used the ABI 3130xl Genetic Analyzer with a 50 cm 16-capillary 
array specialized for sequencing applications and fragment analysis. The capillaries are thin 
(50µm in diameter) glass arrays filled with a separation matrix, in this case with POP-7TM 
Polymer. Separation matrices coat the capillary wall and are specifically optimized to control 
the electrokinetic forces (electrophoresis - the motion of charged particles when applied to an 
electric field, and electroosmosis ± the volumetric liquid flow of the polymer in a capillary 
when applied to an electric field) inflicted from the external voltage applied during capillary 
electrophoresis.  
The sequencing products are injected into the polymer-filled capillaries where the voltage 
applied makes the negatively charged DNA fragments migrate through the polymer towards 
the positive electrode. The mobility of the DNA fragments is proportional to the charged 
particle, which means that smaller fragments with a big charge move faster than larger 
fragments with a small charge. Each DNA fragments are thus injected into the capillary and 
separated by size prior to passing an Argon laser that emits light, which excites the 
fluorescent dyes of the terminating ddNTPs, while a sensor register the color sent back from 
the fluorescent dyes. The results are continuously transferred to a computer and resolved as an 
electopherogram. The velocity of charged particles through the polymer-filled capillary is 
affected by the applied voltage, the length of the capillary array, and the viscosity of the 
polymer, which is also affected by pH and temperature. Polymers with different properties 
can be selected depending on the analytes to be separated (DNA, RNA, proteins, etc.) and the 
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mobility of the analytes can be selectively controlled. Polymers are constantly optimized to 
improve efficiency, selectivity, migration time, and resolution 
(www3.appliedbiosystems.com). 
1.12.6 Dye terminator sequencing kits 
DYE Terminator kits are based on modification of the traditional dideoxy-mediated chain 
termination chemistry where each terminator is labeled with fluorescent dyes for automatic 
detection. Automated cycle sequencing with dye terminators have become the standard of 
choice for most DNA sequencing applications. In this study we used the BigDye® Terminator 
v1.1 Cycle Sequencing Kit, offered by ABI. Each of the four BigDye® terminators (ddG, 
ddA,ddT, ddC) are labeled with a fluorescein donor dye linked to one of the four 
dichlororhodamine (dRhodamine) acceptor dyes; dichloro[R6G] (ddA), dichloro[TAMRA] 
(ddC), dichloro[R110] (ddG), and dichloro[ROX] (ddT). Three of four terminators (ddG, ddT, 
and ddC) are attached to the dRhodamine dye through an ethylene oxide (EO) linker. The 
fluorescein donor absorbs the excitation energy from the argon ion laser which is transferred 
through the EO linker to the dRhodamine acceptor dye that emits fluorescence at different 
wavelengths captured by the sensor. This energy transfer is more efficient than the direct 
excitation of acceptor dyes from the laser which gives a sequencing method that is very 
sensitive and robust (www3.appliedbiosystems.com). 
1.13 Fragment analysis by Capillary Electrophoresis 
Fragment analysis is a powerful tool in molecular biology research used for genotyping, DNA 
profiling, and to detect mutations within a genome. Fragment analysis is the separation of 
DNA fragments by size using capillary electrophoresis, where PCR amplified DNA fragments 
are labelled with multiple fluorescent dyes of different color, including a color-labeled size 
standard of known length to determine the base-pair sizes of the sample product peaks (Figure 
14). The analysis software genotypes the DNA fragments based on user-defined markers 
containing the analysis parameters of the nucleotide of interest 
(www3.appliedbiosystems.com). 
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Figure 14: Overview of the SNaPshot® Multiplex method. The protocol consists of a multiplexed 
PCR step followed by a single-base extension reaction where allele specific probes are fluorescently 
labeled with ddNTPs of different color and sizes that are resolved by capillary electrophoresis (Dias-
Santagata et al. 2010). 
1.13.1 SNaPshot® Multiplex Kit 
The ABI PRISM® SNaPshot® Multiplex Kit is designed to combine up to ten single 
nucleotide polymorphisms (SNPs) at known locations in ten DNA templates that can be run in 
a single tube. The chemistry is based on the dideoxy single-base extension method where 
unlabeled oligonucleotide primer binds to a complementary template and chain elongation is 
terminated by the incorporation of a ddNTP to the 3´ end of the growing strand. The 
terminators (ddG, ddA,ddT, ddC) are labeled with a fluorescein donor dye linked to one of the 
four dichlororhodamine (dRhodamine) acceptor dyes; dichloro[R6G] (ddA), 
dichloro[TAMRA] (ddC), dichloro[R110] (ddG), and dichloro[ROX] (ddT) ± the same donor 
dyes used for the BigDye® terminators (www3.appliedbiosystems.com).    
1.13.2 SNaPshot® Genotyping 
Dias-Santagata et al. (2010) has developed a clinical genotyping assay based on The 
SNaPshot® Multiplex System from Applied Biosystems. The assay is designed to detect 58 
mutations in 13 different cancer genes, and can detect a total of 120 multiple sequence 
variants (i.e. A>T; A>G; A>C) in many of the selected nucleotide positions, including low-
level mutations in formalin fixed and paraffin embedded (FFPE) DNA samples. Only ~20 ng 
DNA pr. reaction is recommend by Dias-Santagata et al. (2010), and the low amount of 
isolated DNA from FFPE tissue required is a major improvement that makes it possible to 
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incorporate FFPE tumor blocks in genetic profiling of cancer patients. Although successful 
mutation profiling are currently conducted from FFPE material, several challenges exists, 
usually from limited amount of available tumor material, low quality of DNA extract, and 
non-reproducible sequence artifacts generated from PCR amplification, which greatly affects 
downstream results (Sah et al. 2013).  
The modularity of the SNaPshot® system reflects the possibilities that lie ahead with 
additional assay modifications. The system is highly robust, sensitive and accurate, easily 
modified, and can be used in any laboratories with an automated DNA sequencer. In 
developing the SNaPshot® Multiplex assay, Dias-Santagata et al. (2010) focused on 
oncogenes over tumor suppressor genes. Oncogenes are often activated by a few mutated 
codons and identifying and inhibiting such activating pathways is a preferred target by clinical 
developers rather than inactivating tumor suppressor genes. Out of 30 CRC cases, Dias-
Santagata et al. GHWHFWHGPXWDWLRQVLQFOXGLQJ³0XWDWLRQVRUFRPELQDWLRQRI
mutations that are rare or not-SUHYLRXVO\GHVFULEHGLQWKHFRUUHVSRQGLQJWXPRUW\SH´6RPHRI
these, i.e. TP53 mutations were found in combination with two other genes (KRAS G13D + 
TP53 R273H and NRAS Q61H + TP53 R175H), strongly suggesting the ability to discover 
novel genetic markers from FFPE tissue with the SNaPshot® Multiplex System. 
1.14 Ion-Torrent PGMTM ± Ion Semiconductor Sequencing 
The new Ion-Torrent technology developed by Life Technologies takes advantage of a 
semiconductor chip device that directly translates chemical signals into digital data. Ion 
semiconductor sequencing is performed without light emitting signals that offer 
unprecedented speed, scalability, and low cost. The chemistry is based on detecting t change 
in pH from the release of protons when DNA polymerase incorporates a dNTP to a growing 
template (Figure 15), with no need for any light fixtures, scanning devices or recording 
cameras to monitor the sequencing by synthesis progression. The Ion Torrent semiconductor 
sequencing chip contains micro-wells filled with a million copies of a DNA molecule. The 
chip is flooded with one nucleotide after another which is incorporated to the DNA sequence 
when it complements the DNA sequence/template in a particular well. The ion sensor directly 
detects the change in pH of that solution and translates it to digital data.  
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Figure 15: Ion Torrent chemistry and chip technology. When DNA polymerase incorporates a 
dNTP a hydrogen ion is released affecting the pH of the solution in the well 
(www3.appliedbiosystems.com). 
First step in workflow is to prepare a library of DNA fragments flanked by the Ion Torrent 
adapters. The Ion Torrent adapters are either ligated to the PCR products or incorporated to 
the 5`-end of the PCR primers. Clonal amplification of the library fragments by emulsion 
PCR coats the Ion SphereTM particles with the DNA template which is then applied to the Ion 
chip. The template coated Ion SphereTM particles is deposited in the chip wells through a 
centrifugation step, and the chip is ready for sequencing (www3.appliedbiosystems.com). 
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2 AIM OF THE STUDY 
Colorectal cancer is a leading cause of cancer related deaths in the western world. The 
challenges to stratify 'XNHV¶stage B patients for correct treatment response are evident with 
the variations in cancer specific survival rates for 'XNHV¶stage B patients. DNA from FFPE 
tissue is routinely used in many diagnostic laboratories to detect mutational biomarkers that can 
predict clinical response, although FFPE derived DNA is often fractionated and yields non-
reproducible sequence artifacts not suitable for Sanger sequencing.  
TP53 has been extensively studied and found mutated in about 50% of all cancers. The breast 
cancer group at EpiGen, Ahus, is participating in the Oslo Breast Cancer Consortium 
(OSBREACC) initiated by K.G. Jebsen Centre for Breast Cancer Research (KGJ CBCR). In 
this regard, TP53 sequencing has been conducted on breast cancer material from Akershus 
University Hospital, but there has never been a screening of TP53 mutations in colorectal 
cancer material from Akershus University Hospital. On this notion we chose TP53 in 
anticipation to achieve new knowledge for colorectal cancer cases at Ahus.    
In this study we are interested to evaluate the SNaPshot® fragment analysis method ideal for 
use on FFPE derived DNA against traditional Sanger sequencing by screening DNA isolated 
from fresh frozen tumors (FFT) and FFPE tumors.  
Distribution of mutations will be analyzed in respect to known clinical and histopathological 
parameters in 'XNHV¶stage B and C cases, and a general mutation analysis of the mutant 
effect on protein function will be theoretically evaluated using the Mut_Mat_II tool available 
from the UMD-p53 database.  
In addition, during the course of this study The Ion Torrent PGMTM machine has been 
implemented at EpiGen and is currently under evaluation by scientist Torben Lüders. We 
thought this was a good opportunity to sequence a small subset of the tumors included in this 
study. 
The aim of this study is therefor to: 
- evaluate three different sequencing based methods on how they perform in detecting 
mutations from DNA isolated from FFT- and FFPE derived tissue 
- analyze the spectrum of TP53 mutations in 'XNHV¶stage B and C cases  
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3 MATERIALS AND METHODS 
3.1 Patient Materials  
Available tumor samples from a consecutive series of 40 fresh frozen colon carcinomas (fresh 
frozen tumors, FFT samples) 'XNHV¶stage B (n = 20) and C (n = 20), removed surgically 
between 2004 and 2007 at Akershus University Hospital (Ahus) (Lørenskog, Norway), were 
included in the present study and analyzed by direct Sanger sequencing for mutations within 
the TP53 gene, exon 2 through 11, including flanking introns.  
In addition, available tumor samples from a consecutive series of 40 paraffin-embedded colon 
carcinomas (FFPE samples) 'XNHV¶stage B (n = 20) and C (n = 20), removed surgically 
between 2010 and 2011 at Ahus, were included in the present study and analyzed by 
SNaPshot® fragment analysis (FA) for mutations in 7 frequently mutated SNPs within codon 
175, 245, 248, 273 and 306, distributed within exon 5, 7, and 8, located in the TP53 DNA 
binding domain.  
FFPE sections were provided and histologically confirmed by pathologist Solveig Norheim 
Andersen at the Department of Pathology, Ahus.  
3.2 Tissue Preparation 
FFPE-blocks were cut into 10 µm-thick sections (5-10 sections) at the Department of 
Pathology and received immediately after microdissection to avoid degradation from oxygen.  
Prior to DNA extraction, FFT tissue PJZDVILQHO\FXWand lysed overnight, while FFPE 
sections were deparaffinized with xylene (Sigma-Aldrich, St. Louis, USA). Residual xylene 
was removed through 2 ethanol (100%; Sigma-Aldrich) rinses. 
3.3 DNA Extraction 
Genomic DNA was extracted from each of the FFT- and FFPE tumors according to the 
DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). This kit is based on a spin-column 
silica-membrane technology that binds DNA while cellular debris and other impurities are 
removed by centrifugation. 
In principle, tissue lysis is loaded on to the spin column with optimal buffer conditions to 
increase the DNA binding affinity to the silica-membrane during centrifugation. Dissolved 
residual salts, cellular debris and contaminants are rinsed through the membrane by 
centrifugation during subsequent washing steps. Membrane-bound DNA is then eluted in 
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buffer solution or water, ready for use. Extracted DNA samples was kept at -20°C and diluted 
prior to amplification to obtain the required concentration specified in the protocols.  
3.4 DNA Quantity and Purity Assessment 
DNA concentration and sample purity was measured using a NanoDrRS7KHUPR
Scientific, Wilmington, DE, USA) spectrophotometer. Maximum absorbance reading is 260 
nm for nucleic acids and 280 nm for proteins. Sample purity assessment of nucleic acids with 
absorbance ratios of A260/280 nm around ~1.8, and A260/230 nm around ~2 is considered to 
be of good quality with little contaminants absorbed at the respective absorbance values. Any 
significant deviations from these values might indicate sample contamination. 
3.5 Ethanol Precipitation 
Isolated DNA from FFT samples with low (<1.0) A260/280 ratio were ethanol precipitated as 
follows; A 1/10 volume (adjusted individually according to each sample volume) of 3 M 
sodium acetate pH 5.2 (Sigma-Aldrich, St. Louis, MO, USA) were added to each sample and 
mixed well. Two volumes of cold 96% ethanol (Arcus, Nittedal, Norway) were added to each 
sample, mixed well, and placed on ice for >20 min, then centrifuged at full speed for 15 min. 
Supernatant was decanted and the pellet was washed in 1 mL cold 70% ethanol (Arcus), then 
mixed briefly before centrifuged at full speed for 2 min. The pellets were air dried and re-
suspended in 50 µL AE buffer (Qiagen) before all tubes were warmed to 37°C for 30 min to 
ensure DNA is homogenized in solution and quantified as described above. Final salt 
concentration in sample should be 0.3 M. The sodium acetate volume is intended for DNA 
suspended in TE-buffer and should be adjusted if DNA is suspended in other solutions 
containing salt, while the ethanol volume should be adjusted according to the amounts of salt 
added. Although DNA was eluted in AE buffer (AE contains 0.5mM EDTA and TE contains 
1 mM EDTA), no sodium acetate or ethanol volumes were adjusted.  
3.6 Primers 
Amplification and extension primers used for direct Sanger sequencing and FA 
(Supplementary Table A) were ordered from Life Technologies (Carlsbad, CA, USA).  
Lyophilized primers were re-suspended in nuclease-free water (Ambion, Austin, TX, USA) 
according to specifications in the primer product data sheet. The primers were diluted to 
obtain the required working solution specified in the respective protocols. Stock solutions and 
aliquots were stored at -20°C. 
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3.7 TP53 Sanger Sequencing Analysis  
Direct sequencing of the TP53 gene, exon 2 through 11 including flanking introns, was 
performed on FFT tumors according to Vu et al. (2008) and IARC (2010) updated protocol 
(only exon 7) (http://p53.iarc.fr/ 2010).  
Direct sequencing of the TP53 gene, exon 5, 7, and 8, including flanking introns was 
performed on FFPE-tumors according Dias-Santagata et al. (2010).  
Several modifications were made to all three protocols according to SPA-protocol 
(Staphylococcal Protein A protocol) regularly performed by the Dept. of Microbiology and 
Infection Control, Ahus. 
3.7.1 PCR Amplification  
Different PCR conditions have been carried out in this study according to which protocol 
followed. Components used in all PCR reactions have been 10X PCR buffer with 15 mM 
MgCl2 (Qiagen), dNTP (Qiagen), forward and reverse primer, HotStarTaq (Qiagen), Q-
Solution (Qiagen), additional MgCl2 (Qiagen), total DNA template, and nuclease-free water 
(Ambion). The amount of each component and PCR cycle conditions are given in detail for 
each protocol (Table 2). 
Table 2: PCR mix (a) and thermal cycle program (b).     
 
1a. Vu et al. (2008) 
 Components  Volume/reaction 
- 10X PCR buffer containing 15 mM MgCl2  1X 
- dNTP mix (2.5mM each)  2.5 nmol (2.5 mM each) 
- Primer, forward and reverse 6 pmol (6µM each)  
- +RW6WDU7DT'1$SRO\PHUDVH8ȝO 0.5U  
- Template DNA  25 ng 
- Water, molecular biology grade  4VSȝL  
 
 
1b. Vu et al. (2008) 
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2a. IARC (2010) 
Components Volume/reaction 
- 10X PCR buffer containing 15 mM MgCl2 1X 
- 5X Q-solution 1X 
- dNTP mix  5 nmol (5 mM each) 
- Primer, forward and reverse  10 pmol (10 µM each) 
- +RW6WDU7DT'1$SRO\PHUDVH8ȝO 0.5U 
- Template DNA 50 ng 
- Water, molecular biology grade 4VSȝL 
 
 
2b. IARC (2010) 
 
 
 
3a. Dias-Santagata et al. (2010)  
Components Amount 
- 10X PCR buffer containing 15 mM MgCl2 1X 
- dNTP mix  4 nmol (4 mM each) 
- Primer, forward and reverse  10 pmol (10 uM each) 
- +RW6WDU7DT'1$SRO\PHUDVH8ȝO 0.5U 
- additional MgCl2 Ref 
- Template DNA 40 ng 
- Water, molecular biology grade 4VSȝL 
Ref: Supplementary Table B 
 
 
3b. Dias-Santagata et al. (2010)  
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3.7.2 Optimization of PCR- and Cycle Sequencing Parameters  
6RPH))3(VDPSOHV¶LQLWLDO3&5DPSOLILFDWLRQUHYHDOHGQREDQGVRUWKHILQDOVHTXHQFLQJ
results failed due to poor data quality when processed according to the sequencing protocol by 
Dias-Santagata et al. (2010). PCR cycle conditions were in those cases increased from 38 to 
48 cycles. Excess primers and unincorporated dNTPs were inactivated as described under 
section 3.7.4.  
Newly amplified PCR products were then purified according to the silica-based QIAquick 
3&53XULILFDWLRQ.LW4LDJHQDVUHFRPPHQGHGE\WKHPDQXIDFWXUHUV¶UHFRPPHQGDWLRQV
Thermal cycling conditions were also increased from 38 to 48 cycles, and all samples were 
further analyzed as described.  
3.7.3 Gel Electrophoresis 
All PCR products were analyzed on 1.5% (w/v) Sea Kem LE agarose gel (Lonza, Rockland, 
ME, USA) in 1X Tris-Borate-EDTA (TBE) buffer (1L: 54 g Tris-base, 27.5 g boric acid, 20 
mL 0.5 M EDTA (pH 8), nuclease-free water, Department of Microbiology and Infection 
Control, Ahus). The gel was stained with SYBR Safe® (Invitrogen, Carlsbad, CA, USA) DNA 
gel stain (2µL/50mL). 2 µL PCR products with 1.5 uL of 10X gel loading dye (Orange G) 
were loaded onto the gel. A Low Mass DNA ladder (Invitrogen) was included in all runs to 
quantify the amount of PCR products, along with positive (human DNA (Invitrogen)) and 
negative controls (blank). 
The gel was run in 1X TBE at 200V for 25 min. The migrated DNA bands were visualized 
under Bio-Rad GelDoc XR (BIO-RAD, Hercules, CA, USA) imaging system and captured as 
*.jpg files. 
3.7.4 Purifying PCR Products  
PCR products from FFT samples were initially purified on a vacuum manifold with the 
ultrafiltration-based MinElute 96 UF PCR Purification Kit (Qiagen) according to 
PDQXIDFWXUHUV¶UHFRPPendations.  
For the modified Vu and IARC protocols, PCR products from FFT samples were diluted 1/10 
with nuclease-free water prior to use in sequence reaction mix according to the SPA protocol. 
Excess primers and unincorporated dNTPs in FFPE samples were inactivated with 1U of 
shrimp alkaline phosphatase (SAP) (USB, Cleveland, OH, USA) and 5U of exonuclease I 
(Exo I) (USB) at 37°C for 20 min, followed by enzyme inactivation at 80°C for 15 min.  
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3.7.5 Sequence Reaction 
Components for each sequence reaction mix was carried out iQDWRWDOYROXPHRIȝ/
containing 10X Sequencing buffer (Life Technologies, Carlsbad, CA, USA), Big Dye 
Terminator reaction mix v1.1 (Life Technologies), forward or reverse primer, purified PCR 
product template, and nuclease-free water (Ambion) up to final volume. The amount of each 
component and thermal cycle conditions for each protocol are given in detail (Table 3). 
Table 3: Sequencing mix (a) and thermal cycle program (b) 
 
1a. Vu et al. (2008)   
 Components  Volume/reaction 
- 10X Sequencing buffer  ȝO 
- Big Dye Terminator reaction mix v.1.1  ȝO 
- Primer, fwd. or rev. 8 µM  ȝO 
- PCR Product template (purified) 2 µl 
- Water, molecular biology grade  4VSȝO 
 
 
1b. Vu et al. (2008) 
 
 
 
2a. Vu et al. (2008) and IARC (2010) according to SPA  
Components  Volume/reaction 
- 10X Sequencing buffer  1.5 ȝO 
- Big Dye Terminator reaction mix v.1.1  1 ȝO 
- Primer, fwd. or rev. 8/10 µM  ȝO 
- PCR Product template (purified) 2 µl 
- Water, molecular biology grade  4VSȝO 
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2b. IARC, 2010  
 
 
 
 
3a. Dias-Santagata et al. (2010) according to SPA 
Components  Volume/reaction 
- 10X Sequencing buffer  1.5 ȝO 
- Big Dye Terminator reaction mix v.1.1  1 ȝO 
- Primer, fwd. or rev. 10 µM  ȝO 
- PCR Product template (purified) 2 µl 
- Water, molecular biology grade  4VSȝO 
 
 
3b. Dias-Santagata et al. (2010)  
 
3.7.6 Purifying Sequencing Products 
Sequencing products from FFT samples were initially purified on a vacuum manifold with the 
ultrafiltration-based Montage SEQ96 Sequencing Reaction Cleanup Kit (Millipore, Billerica, 
MA, USADFFRUGLQJWRPDQXIDFWXUHUV¶UHFRPPHQGDWLRQV 
For the modified Vu, IARC, and Dias-Santagata protocols, sequencing products from FFT- 
and FFPE samples were purified by isopropanol precipitation according to the SPA protocol 
as follows; sequencing products were precipitated by adding 90 µL 69% isopropanol (Arcus) 
to each tube and incubated at the bench top for 15 min. The precipitate was centrifuged in an 
Eppendorf Centrifuge 5810R (Epperndorf, Hamburg, Germany) at 21°C and 3000 g for 30 
min with the centrifuge acceleration set at 8 and the break set at 5. Carefully removed from 
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the centrifuge the tubes were turned upside-down for the isopropanol to quickly run off. The 
tubes were directly centrifuged upside-down on a tissue at 21°C and 700 g for 1 min, with the 
centrifuge acceleration set at 4 and the break set at 1. The slow acceleration and breaking is 
necessary to avoid the sequencing products to be thrown out of the tubes by excess force.  
3.7.7 Sequencing ± Capillary Electrophoresis 
Vacuum purified sequencing products from FFT samples were directly loaded on to a 
sequencing plate which was covered with septa and briefly spun down. The samples were run 
on 3730 Genetic Analyzer (Applied Biosystems® (ABI), Carlsbad, CA, USA) with POP-
sieving polymer in 50cm capillaries of standard run module, and bases were called by .%
Basecaller v1.4 with Dyeset E and mobility file KB_3730_POP7_BDTv1.mob (ABI). 
For the modified Vu et al. (2008), IARC, and Dias-Santagata et al. (2010) protocols, 
sequencing products from FFT- and FFPE samples were processed according to the SPA-
protocol as follows; 12µl HiDi formamide (Life Technologies) was added to the precipitated 
sequencing products and prepared appropriately as described above. The samples were run on 
3130xl Genetic Analyzer (ABI) with POP-VLHYLQJSRO\PHU in 50 cm capillaries with 
standard run module, and bases were called by .%%DVHFDOOHUYwith Dyeset E and 
mobility file KB_3130_POP7_BDTv1.mob (ABI). 
3.7.8 Data Analysis - SeqScape® Software Version 2.6 (ABI) 
Sequence data generated on ABI 3730 and 3130xl DNA ANALYZERs were analyzed for 
mutations with SeqScape® Software Version 2.6 (ABI). A p53 project template with genomic 
reference sequence (NT_000017.9) of defined exon-intron boundaries and analysis settings 
for automatic analysis was obtained from Phoung Vu at the Department of Genetics, 
Norwegian Radium Hospital, Oslo, Norway.  
Assembled sequencing results (*.abi trace files) were aligned into a consensus sequence and 
manually reviewed for basecalling accuracy against the reference sequence. Sequence 
coverage and clear range was checked for each samples¶ trace file, and filtered sequences with 
low quality regions were trimmed for clear range and assembled when possible. 
3.8 TP53 SNaPshot® Fragment Analysis 
Fragment analysis of selected TP53 nucleotide positions (Supplementary Table C) were 
performed on FFPE samples according to Dias-Santagata et al. (2010).  
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Also, a fraction of tissue was taken from 3 of the FFTs for formalin fixation and paraffin wax 
embedding. The three samples were then analyzed accordingly to verify mutations found by 
direct Sanger sequencing within these tumors. Paraffin blocks of FFT tissue were cast at the 
Department of Pathology, Ahus, and histologically confirmed by pathologist Solveig Norheim 
Andersen, Dept. of Pathology, Ahus. 
3.8.1 PCR Amplification 
3&5UHDFWLRQVZHUHFDUULHGRXWLQDWRWDOYROXPHRIȝ/FRQWDLQLQJ;3&5EXIIHUZLWK
mM MgCl2 (Qiagen), 2.5 mM of each dNTP (Qiagen), 1U HotStarTaq (Qiagen), the correct 
amount of each forward and reverse primer (Supplementary Table D), ~25 ng genomic DNA 
template, and nuclease-free water (Ambion) up to final volume.  
PCR cycle conditions were 95°C for 8 min of enzyme activation, followed by 45 cycles of 
denaturing at 95°C for 20 sec, annealing at 58°C for 30 sec, and extension at 72°C for 1 min, 
and one last cycle of extension at 72°C for 3 mLQZLWKLQGHILQLWHVWRUDJH& 
DNA from FFPE tissue is often fragmented with low quality. This restricts the amplicon 
length parameters to a maximum of 200 nt. All final PCR product length varies between 75-
187 nt. 
3.8.2 Purifying PCR Products  
Inactivation of excess primers and unincorporated dNTPs was done with 3.3U of SAP (USB) 
and 2.7U of Exo I (USB) at 37°C for 60 min, followed by enzyme inactivation at 75°C for 15 
min. 
The PCR products were analyzed by gel electrophoresis as described under section 3.7.3. 
3.8.3 Labeled Primer Extension Reaction 
3ULPHUH[WHQVLRQUHDFWLRQPL[ZDVFDUULHGRXWLQDWRWDOYROXPHRIȝ/Fontaining 1-2 µL of 
PCR product (determined from a dilution series test), 2.5 µL SNaPshot® Multiplex Ready 
Reaction mix (ABI), the correct amount of extension primers (Supplementary Table E), and 
nuclease-free water up to final volume.  
Thermal cycling conditions were 96°C for 30 sec, followed by 25 cycles at 96°C for 10 sec, 
&IRUVHFDQG&IRUVHFZLWKLQGHILQLWHVWRUDJH& 
3.8.4 Purifying Extension Products  
Inactivation of excess extension primers was done with 2U of SAP (USB) at 37°C for 60 min, 
followed by enzyme inactivation at 75°C for 15 min.  
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3.8.5 SNaPshot® Genotyping 
0.5 µL inactivated labeled extension products were mixed with 0.2 µL GeneScanTM 120 LIZ® 
(ABI) and 9.3 µL HiDiTM Formamide (ABI) and denatured at 95°C for 5 min. The sequencing 
products were mixed thoroughly and transferred to a sequencing plate which was covered 
with septa and briefly spun down. The samples were run on ABI 3130xl Genetic Analyzer 
with POP-7TM sieving polymer in 50 cm capillaries, and ABI GeneScan E5 Run Module. 
3.8.6 Data Analysis - GeneMapper® Software Version 4 (ABI) 
SNaPshot® results were analyzed for mutations with The Applied Biosystems GeneMapper® 
Software Version 4, according to the default settings defined for SNaPshot® analysis. Panels 
and bin set parameters for automatic data analysis was provided as text files (Dias-Santagata 
et al. 2010).  
All samples (*.fsa trace files) were manually reviewed for genotyping, and scoring criteria 
was calculated for all samples. 
Each sample passed if WKHSHDNIOXRUHVFHQWKHLJKWIRUWKHZLOGW\SHDOOHOHZDV-100 times 
higher than the overall background noise, and if the peak fluorescent height for the wild type 
allele in the negative control (water sample) was < 10% of the height of the wild type allele in 
the clinical sample.  
A positive mutation was called when the percentage of mutant allele ZDVIOXRUHVFHQW
peak height ratio of [mutant/(mutant+wild type)] alleles > 0.10), and if the peak fluorescence 
of the mutant allele was > 3 times above the background in the wild type control sample.  
3.9 Ion-Torrent PGMTM Sequencing 
Ion-Torrent sequencing was performed on a small selection of FFT- and FFPE samples with 
the Ion AmpliSeqTM Library Kit 2.9 and Cancer Hotspot Panel v2 according to 
manufactuUHUV¶SURFHGXUHV, carried out by scientist Torben Lüders at EpiGen, Ahus.  
3.10 Statistical Analysis  
Minitab® 16 was used to perform Fishers¶H[DFWWHVWto establish association between the two 
groups of 'XNHV¶stage B and C.  
3.10.1 Clinicopathological Analysis 
Univariate, Kaplan-Meier analyses and the log-rank test Į  for two parameters: TP53 
and 'XNHV¶stage was performed to investigate how these parameters affect survival. KM-plot 
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was kindly computed by Post. Doc. Jovana Klajic (EgiGen, Ahus) using the SPSS Software. 
Overall survival was defined as date of operation to death from colon cancer, or to the last 
known follow-up date.  
Microsoft Excel 2010 was used for Pearson´s correlation of coefficients between 
clinicopathological pairs of variables.  
3.12 Stock Solutions  
3.12.1 Orange G  
;*HO/RDGLQJ'\HZDVSUHSDUHGE\GLVVROYLQJJVXFURVH*&6LJPD-Aldrich) 
and 100 mg Orange G (Sigma-Aldrich) in 40 mL nuclease-free, then topped with nuclease-
free water (Ambion) to a final volume of 50 mL.  
3.12.2 Buffer PB 
Qiagen Buffer PB stock solution was prepared by dissolving 47,765g Gu-HCl (Sigma-
Aldrich) in 30 mL 100% isopropanol (Arcus) and topped with nuclease-free water (Ambion) 
to a final volume of 100 mL.  
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4 RESULTS 
In this study we have used three different sequencing methods to investigate the ability to 
detect somatic mutation in CRC-tumor samples from FFT- and FFPE tissue (Figure 16). This 
chapter reflects the results obtained from these experiments.  
  
Figure 16: Overview of each experiment performed in this study on FFT- and FFPE-tissue.                              
Text in red represents failed analyses. 
From a total of 80 samples chosen for this study, 77 were successfully analyzed. Three FFT 
specimens were excluded; one specimen was not found, one specimen failed to yield any 
DNA extract, and one specimen was incorrectly labeled as 'XNHV¶stage C when it in fact was 
'XNHV¶stage D. 
4.1 DNA Sample Quality Assessment 
To ensure reproducible results in downstream applications it is important to assess DNA 
sample purity to determine contaminants such as proteins, salts and solvents. DNA prepared 
from tissue usually has high protein content. A low (<1.8) A260/A280 ratio is indication on 
protein contamination, and a low (<1.5-1.8) A260/A230 ratio is indication on salt carryover 
from the DNA isolation process. Lower A260/A230 ratios indicate higher salt content.  
Absorbance readings of A260/A280 ratio measured in DNA purified from FFT tissue were in 
the range of 1.70-2.33, with the majority within 1.70-2.0. The A260/A230 ratio varied from 
0.30-2.24. Twenty-one samples with A260/A230 ratio <1.0 were ethanol precipitated which 
increased the A260/A230 ratio from <1.0 to ~1.8-2.0 in the respective samples. Ideally, the 
A260/A230 ratio should be close to 1.8, but greater than 1.5. However, 8 FFT samples with 
A260/A230 ratio >1.0<1.5 were not ethanol precipitated.  
DNA isolated from FFPE tissue had A260/A280 ratio of ~2.0. A low (<1.0) A260/A230 ratio 
were seen in most samples, however, these were not ethanol precipitated.  
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The complete list of absorbance reading values and extracted amount of DNA (ng/µl) from 
FFT- and FFPE samples, including ethanol precipitated samples, are given in Supplementary 
Table F. 
4.2 TP53 Direct Sanger Sequencing Analysis  
We aimed to amplify exon 2-11 of the TP53 gene in the FFT samples according to Vu et al. 
(2008) with slight modifications. Most samples produced target amplicons (verified by 1.5% 
agarose gel electrophoresis) of varying band strength from each primer pair covering exon 2-
3, 4, 5-6, 7, 8-9, 10, and 11 (Figure 17), except one specific sample that failed in each run (see 
Figure 18 for representation). Fragment length varies between 396-733 bp (see 
Supplementary Table A for details). 
 
Figure 17: TP53 target PCR amplicons obtained from FFT samples. Extract of 8 
consecutive specimens identical in each gel image. Most samples failed amplification 
for exon 2-3 and 4.   
Target amplicons for exon 7 from the new and improved IARC protocol (Figure 18) were 
obtained from all FFT samples, including the one sample that did not produce any amplicons 
for any of the primer pairs according to Vu et al. (2008). 
          
Figure 18: TP53 target PCR amplicons obtained from FFT samples. (A) Target amplicons for 
exon 7 according to the improved IARC 2010 protocol. (B) Exon 11 according to Vu et al. 
(2008). Both gel images contains 38 samples in consecutive order, including positive (genomic 
human DNA), negative (blank) control, and Low mass DNA ladder as reference. Each sample in 
image B was run with an accompanying negative control, represented by the continuous gap of 
empty wells between bands of DNA. The white dot in image A and B represents one specific 
sample that failed (B) to obtain PCR target amplicons according to Vu et al. (2008) (results not 
shown for all exons) versus the amplicon obtained (A) according to the improved IARC protocol.   
 
 
400bp -  
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Initially we tried to amplify FFPE derived DNA for exon 5-6 and 8-9 according to Vu et al. 
(2008) and exon 7 according to IARC, since these primer pairs were already in our 
possession. Target amplicons were obtained for exon 7 according to IARC, but no amplicons 
were obtained for exon 5-6 and 8-9 according to Vu, et al. (2008) (results not shown). New 
primer pairs for exon 5, 7, and 8 (Figure 19), were ordered according to the sequencing 
analysis protocol from Dias- Santagata, et al. (2010). Since the Dias-Santagata protocol is  
                                                                                 
Figure 19: TP53 PCR target amplicons obtained 
from FFPE samples. (A) Target amplicons for 
exon 8 failed for 22 of 40 samples at first attempt of 
PCR cycling. Gel image A contains 40 samples in 
consecutive order including positive (genomic 
human DNA), negative (blank) control, and Low 
mass DNA ladder as reference. (B) In total, 29 of 40 
samples from image A were re-amplified with PCR 
cycles increased from 38 to 48 cycles, then spin-
column purified.  
 
optimized for FFPE derived DNA we decided to include primer pairs for exon 7, although this 
exon obtained successful amplicons with the IARC protocol. However, in a downstream test 
run sequencing results were undesirable, and to save costs from sequencing reactions we only 
decided to amplify and sequence exon 8 due to the fact that PCR amplification of FFPE 
samples for sequencing purpose was performed after the SNaPshot® fragment analysis was 
completed, and we found it crucial to verify the results obtained in codon 273 by sequencing 
exon 8 (Figure 26). 
4.2.1 Sequence Data 
ABI 3730 
Most FFT samples resolved on the ABI 3730 DNA analyzer were unassembled and failed 
basecalling analysis due to poor data quality. The assembled sequences showed irregular and 
uneven trace peaks with dye blobs and background noise (Figure 20, A1 and A2) throughout 
all chromatograms (not all results shown).  
ABI 3130xl 
FFT samples resolved on the ABI 3130xl analyzer were successfully assembled with regular 
and even trace peaks, and minimal background noise (Figure 20, B1 and B2) throughout the 
chromatograms. However, forward sequences generated for exon 7 (Vu et al. 2008), 
2000bp 
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200bp 
100bp 
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400bp 
200bp 
100bp 
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amplification primer 5´-GACCATC CTGGCTAACGG-3´ and universal M13 extension 
primer) resolved multiple sequences (Figure 20, C1) in all samples. New forward sequences 
generated for exon 7 (IARC) were successfully assembled with regular and even trace peaks, 
and minimal background noise (Figure 20, C2).  
Sequencing results obtained from FFPE samples were generally of poor quality with the 
majority being unassembled. Assembled sequences showed irregular trace peaks with 
considerable background noise (Figure 21). From unassembled FFPE samples that were re-
amplified with increase in PCR and cycle conditions and spin-column purified, the overall 
background noise was reduced (Figure 22). The reduced noise was not compared to 
sequencing results of corresponding samples prior to and after reamplification. 
 
Figure 20: Sequencing results from FFT samples. Blue bars indicates QV scores (QV=20). (A1 
and A2) Both samples were resolved on ABI 3730 with dye blobs caused by unincorporated or 
incomplete removal of dye terminators (only forward sequences were assembled). (B1 and B2) 
The same samples as shown in A1 and A2 after modifications according to SPA and resolved on 
ABI 3130xl. (C1) All forward sequences for exon 7 resolved multiple sequences according to Vu 
et al. (2008). Double peak in reverse strand can be a mutation or a PCR-artifact. (C2) Improved 
quality of exon 7, according to IARC/SPA, resolved a clean uniform sequence, and the double 
peak can be defined as a heterozygous mutation. 
codon 233 CAC codon 233 CAC 
codon 192 CAG 
codon 192 CAG 
codon 192 CAG 
codon 192 CAG 
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Five of 6 mutations detected by SNaPshot® genotyping were verified by Sanger sequencing 
and all false positive mutations detected by FA in codon 273 were verified as wild-type allele 
(Figure 21 and 22) (not all results shown).  
Figure 21: Sequencing results from 
FFPE samples. Vertical marker is at 
codon 273 (CGT), exon 8, and show 
wild-type in all three FFPE samples. 
Overall noisy trace files with many 
secondary peaks makes it difficult to 
interpret real mutations. FFPE 1 and 
9 are fragmented with shortened clear 
range.   
 
 
Figure 22: Sequencing results from purified FFPE samples. (A) Vertical marker is at codon 
273 (CGT), exon 8 and show wild-type in all three samples. In sample FFPE 10 there is a 
heterozygous mutation in codon 282 (CGC) seen by a double red and blue peak (arrow). (B) 
Vertical marker defines a possible deletion in codon 283 (CGC). All 3 samples shown in this 
figure had been re-amplified and spin-column purified with increase in PCR and cycle conditions. 
 
4.3 TP53 SNaPshot® Fragment Analysis of FFPE  
The SNaPshot® assay developed by Dias-Santagata et al. (2010) contains 13 mutated genes 
and can detect a total of 120 nucleotide variants. We exclusively focused on the TP53 gene 
originally multiplexed into 5 panels. Two panels contain the same PCR amplification primer 
which was run as a uniplex PCR reaction (Figure 23). All FFPE samples produced successful 
target amplicons (verified by 1.5% agarose gel electrophoresis) (not all results shown).  
codon 273 CGT 
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Figure 23: TP53 target PCR amplicons obtained from FFPE samples. Gel image of 7 samples in 
consecutive order, including positive (genomic human DNA) in the first 3 rows of bands (8 wells) and 
negative (blank) control in the last row (7 wells), with Low mass DNA ladder as reference. Each row 
of bands represents SNaPshot panels containing the TP53 nucleotide position of interest. 
Sequencing results of FFT samples revealed a total of 3 mutations that can be detected by the 
SNaPshot® assay. A fraction of these tumors were formalin fixed and paraffin wax embedded, 
and isolated DNA was PCR amplified according to Dias-Santagata et al. (2010). Successful 
amplicons were obtained for 2 of 3 samples (results not shown). 
4.3.1 SNaPshot® genotyping 
SNaPshot® genotyping results from automatic data analysis were manually examined to check 
for each of the necessary parameters being passed by the GeneMapper software. Allele peak 
height was optimized through a series of extension product dilutions to determine the 
appropriate amount of extension products for genotyping (Figure 24). All FFPE samples were 
successfully genotyped (Figure 25) in 6 of 7 detectable mutations, except for codon 273 
(c.817C>T), in which false positive results (Figure 26) were obtained in 39 of 40 FFPE 
samples. Paraffin embedded FFT samples did not pass automatic data analysis (Figure 27). A 
secondary peak is observed in sample CRC 204, although it was not automatically genotyped 
as a mutation. Panels and bin settings were evaluated for all results and scoring guidelines 
was calculated for each genotyped mutant allele (Supplementary Table G).  
      
Figure 24: SNaPshot® genotyping results. Raw files with GeneScanTM 120 LIZ size standard 
and miniature chromatogram of wild-type sample. Both samples are from diluted PCR product 
(1:20). (A) A much diluted sample that failed the automatic data analysis settings. (B) 
Appropriately diluted sample that passed the automatic data analysis settings.  
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Figure 25: Successful SNaPshot® genotyping vs Sanger sequencing results. (A) Successful 
SNaPshot® genotyping of 2 FFPE samples. (B) Marker position is codon 248 (CGG). Mutations 
from SNaPshot® genotyping are verified by Sanger sequencing. Expanded top view show three 
peaks which makes the mutation difficult to interpret alone.  
 
 
Figure 26: False positive genotyping. 
SNaPshot® genotyping of false positive 
mutations positioned at c.817C>T, 
codon 273. All samples passed data 
analysis.  
  
 
  
 
Figure 27: SNaPshot® 
Genotyping sensitivity vs 
Sanger sequencing. (A) 
SNaPshot® genotyping of 
paraffin embedded FFT 
samples. Each sample failed 
automatic data analysis 
criteria. (B) Heterozygous 
mutation detected by 
Sanger sequencing in CRC 
204 that failed SNaPshot® 
genotyping (A). 
  
 
A B 
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4.4 Ion-Torrent PGMTM 
Ion Torrent sequencing detected each of the mutations found in the subset of 4 FFT- and 4 
FFPE samples selected for semiconductor sequencing. The DNA base composition of 
suspected deletions found by Sanger sequencing were determined, and missense mutations 
were verified (Table 4). One FFPE sample was wild-type for all TP53 exons (result not 
shown). 
4.5 Cancer Analysis  
4.5.1 TP53 Mutations  
Among the 77 tumors analyzed, 26 (33.8%) tumors revealed a total of 27 mutations within 
exon 5-9 of the TP53 gene; an overall frequency of 33.8%. The specific DNA sequence 
alteration was identified for all 27 mutations (Table 5). The frequency of each individual 
mutation recorded in the IARC TP53 and UMD-p53 database (Figure 28) are mostly hot-spot 
and frequent mutations.  
No statistical significance (2-sided )LVKHU¶VH[DFWWHVWZHUHVHHQEHWZHHQWKHGLVWULEXWLRQRI
PXWDWLRQVZLWKLQ'XNHV¶%DQG&FDVHVp = 1), or between the distribution of 
mutations by metastases (p = 1).  
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4.5.2 Effect of TP53 Mutations 
The effect of TP53 mutations were in total 18 (66.7%) missense mutations, 4 (14.8%) 
nonsense mutations, 4 (14.8%) deletions, and 1 (3.7%) double missense (tandem) mutation 
(Figure 29A). The majority of the mutations were found within exon 8 (Figure 29B). Since 
only exons 5-9 were investigated in this study, these results are slightly biased as mutations 
are distributed throughout all coding exons (exons 2 through 11) of the TP53 gene (Figure 
29C).  
 
 
Figure 29: Effect of TP53 
mutations. (A) Pie-chart of 
mutational effect. Missense 
mutations accounts for the 
majority of mutations found in 
this study. (B) Effect of TP53 
mutations distributed by exon 
number. A majority of the 
mutations were found in exon 8. 
(C) Distribution of p53 
mutations in the various 
functional domains of p53. Top 
bar: functional domains 
(Hjortsberg et al. 2008).  
 
4.5.3 TP53 Mutational Events and CpG dinucleotide 
The most frequent type of mutations were purine to purine (G>A, 40.7%) transitions followed 
by pyrimidine to pyrimidine (C>T, 26%) transitions. Other transitions (A>G, 3.7%; T>C, 
3.7%) and transversions (G>T, 7.4%), including deletions (14.8%) and double mutation 
(tandem) (3.7%) were less frequent (Figure 30A).  
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Figure 30: Distribution of mutational events at non-CpG and CpG dinucleotide. 
(A) Distribution of mutational events at non-CpG and CpG sites found in 'XNHV¶
stage B and C patients in current study. (B) Mutational events at non-CpG and CpG 
sites in colorectal carcinomas reported in the UMD-p53 database (Hjortsberg et al. 
2008).  
A total of 17 (63%) mutations were found at CpG dinucleotide, predominantly as G>A and 
C>T transitions (Figure 30A). However, mutations at CpG dinucleotide in colon carcinoma 
are dominated by GC->AT transitions with no reports of AT>GC transitions or any 
transversions in the UMD p53 Mutation database (Figure 30B). 
4.5.4 p53 Mutant Activity 
p53 mutant activity was analyzed through the UMD-p53 Mutation database spreadsheet, 
MUT_MAT_II (MUT-TP53 2.0, April 19th, 2014). Four deletions were excluded in the 
spreadsheet as only exonic missense mutations are allowed entered. Comments generated by 
the spreadsheet (Supplementary Table H) on mutant activity are the basis for the results 
reported in this section. Out of 23 mutations analyzed, 18 (78.3%) resulted in inactive 
proteins, 4 (17.4%) resulted in truncated proteins, and 1 (4.3%) did not display any significant 
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loss of protein activity. The excluded deletions were added to the pie-chart for a full 
representation of the mutation spectrum found in this study (Figure 31).  
 
Figure 31: Activity of mutant p53 protein. Activity of mutant p53 protein was generated in UMD 
p53 spreadsheet MUT_MAT_II (MUT-TP53 2.0). Pie chart showing >50% of the mutations resulted 
in inactive protein. A truncated protein represents nonsense mutations. 
4.5 Survival Analysis 
All tumors were adenocarcinomas classified as 'XNHV¶Stage B (n = 39) or C (n = 38). From a 
total of 77 patients, 9 patients (wt (n = 4) and mut (n = 5)) were excluded from further 
analysis because clinical information was missing for these patients (clinical data not shown). 
Survival time was defined from date of diagnosis to date of death from colorectal cancer, or to 
the last known follow-up date (censored observations), measured in months. Of the remaining 
68 patients (Supplementary Table I) ('XNHV¶stage B (n = 34) and C (n = 34)), 21 were TP53 
mutant and 47 were TP53 wild-type. At closing date (July 2013) 44 patients were alive of 
which 2 were wild-type with metastasis, and 27 wild-type and 15 mutants without metastasis. 
In total, 24 patients had died; 17 of 19 patients with metastasis (wt (n = 14) and mut (n =5)) 
had died from colorectal cancer, while 7 patients without metastasis had died from other 
causes. Median age for all patients was 70.5 years (range from 42 to 89 years). Median 
observed time of complete months lived (for all patients alive or dead) was 26.3 months 
(range from 0.1 to 97.6 months). Median observed time until last follow up date was 33 
months (ranging from 0.7 to 97.6 months). Median observed time until metastasis was 3.3 
months (range from 0 to 27.9 months). Median observed time until prime site recurrence (4 
'XNHV¶stage B (wt (n = 2) and mut (n = 2)) was 37 months (range from 0.4 to 97.6 months). 
Median observed time from date of diagnosis until death occurred was 13.8 months (range 
from 0.1 to 54.8 months).  
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To investigate which parameters contribute to differences in survival we applied univariate 
analysis using Kaplan-Meier modeling and the log-rank test for two clinical parameters: TP53 
mutation status and 'XNHV¶stage. Survival analysis identified 'XNHV¶stage as significant 
predictor of overall survival. The Kaplan-Meier plot showed a non-significant difference in 
survival between TP53 wild-type and mutant patients (Figure 32A). A significant difference 
in survival was seen EHWZHHQ'XNHV¶VWDJH%DQG&WXPRUVZKHUHVWDJH&patients have 
significantly worse prognosis (Figure 32B). Metastasis free survival stratified by TP53 status 
(n = 7) could not be analyzed as all patients that had metastasis at time of diagnosis (n = 10) 
were excluded. Correlation between TP53 status and clinicopathological characteristics are 
EDVHGRQ3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQWSupplementary Table J). 
     
Figure 32: Overall patient survival according to the TP53 mutation status and 'XNHV¶VWDJH. 
(A) No difference in survival was identified between wild-type TP53 and mutant TP53 patients.  
(B6XUYLYDOGLIIHUHQFHVEHWZHHQ'XNHV¶VWage B and C identified Duke´s stage C tumors to have 
significantly worse prognosis.  
 
 
 
 
 
 
 
 
 
 
A            B 
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5 DISCUSSION 
5.1 Statistical Inconsistency of Methods 
The number of mutations that can be detected by Sanger sequencing depends on the number 
of exons that is sequenced within the gene of interest. In contrast, fragment analysis is an 
allele-specific detection method that tests a sequence change at a specific site, which also 
makes it difficult to distinguish the mutational mechanism (e.g. point mutation vs. insertions 
or deletions). 
Dias-Santagata et al. (2010) has designed a SNaPshot® Multiplex assay that can detect 58 
mutations across 23 exons in 13 critical cancer genes. For this study we focused exclusively 
on the TP53 gene that is 393 codons long, while the SNaPshot® assay is designed to detect 7 
SNPs within 5 codons in the DNA binding domain.  
Due to the different amount of somatic mutations that can be detected between Sanger 
sequencing (all exons and flanking introns) and fragment analysis (selected SNPs), any 
significance between results obtained cannot be statistically determined.  
5.2 Differences in Mutation Detection  
DNA sequencing technology has improved our understanding of biological processes, and the 
discovery of novel DNA biomarkers has helped to determine treatment outcome in many 
diseases. With the increased throughput of NGS, multiple genes and whole genomes can now 
be extensively assessed in contrast to sequencing single genes as traditionally performed with 
Sanger sequencing (Soussi 2011).  
Tumor sequencing projects has discovered thousands of passenger mutations found coselected 
by driver mutations involved in sustaining carcinogenesis, and many of these passenger 
mutations are found in non-coding regions. Mutations are thus not confined to hot-spot or 
frequent mutations at known sites, but occur throughout the whole region of TP53 (Soussi 
2011).  
The number of mutations that were detected by Sanger sequencing reflects many potentially 
undetected mutations when focusing on a few pre-selected SNPs (Supplementary Table E). In 
addition, our results are also biased and do not reflect the true TP53 mutation spectrum 
potentially identified in the studied cohort, since we only focused on exon 5 through 9. The 
decision for this was twofold; after experiencing several problems in our initial sequencing 
runs (discussed below) we decided to focus on exon 5 through 9, since these regions contains 
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the SNPs that is targeted by the SNaPshot® assay, and we saw the need to reduce the 
workload for the purpose of this study.  
5.3 Experimental Procedures and Optimization of Protocols 
5.3.1 Sanger Sequencing 
Our initial attempt to sequence TP53 according to Vu et al. (2008) (with slight modifications) 
was unsuccessful in several ways. First, the vacuum manifold was defect and out of order 
(personal communication, Post. Doc. Tone Tannæs, EpiGen, Ahus). Secondly, the ABI 3730 
DNA Analyzer was vacant at the onset of our experiments and the installed capillaries were 
most likely dried out and of old age (2 years). Although not elucidated in detail, both of these 
issues most likely had an effect on the poor results obtained on the ABI 3730 DNA analyzer. 
These initial problems led us to adapt parts of the SPA protocol already optimized and 
implemented at the Dept. of Microbiology and Infection Control, Ahus, which was performed 
on the ABI 3130xl DNA Analyzer, with very clean trace file results.       
According to Vu et al. (2008), forward sequences for exon 7 produced trace phase shifting 
event (TPSE) with mixed peaks 3´ of the motif in the chromatogram (Figure 20 C1). These 
TPSEs were caused by PCR stutter when the polymerase slips during the amplification of 
mono- or di-nucleotide repeats of a certain length. Stutter in exon 7 forward sequences was a 
known problem with the current protocol and a new and improved protocol had been 
published in the IARC TP53 database (personal communication, scientist Phuong Vu, 
Department of Genetics, Radium hospital, Oslo). The TPSEs were eliminated in all forward 
sequences according to the new IARC (2010) protocol (Figure 20 C2).  
Since we only wanted to verify mutations detected by the SNaPshot® assay, Sanger 
sequencing of FFPE samples were confined to the respective exon where the mutation was 
detected, including exon 8 for all false-positive results (n = 39/40) (discussed below). Many 
FFPE samples did require additional PCR- and sequencing runs, including extra PCR-
purification step, and these FFPE samples performed well with Sanger sequencing.       
5.3.2 SNaPshot®  
The SNaPshot® multiplex assay designed by Dias-Santagata et al. (2010) is ideal for use on 
FFPP derived DNA. Although designed for 13 genes, we solely focused on TP53 and did not 
evaluate possible co-occurring mutations in other genes included in the assay.   
Encountered issues involved optimizing the amount of extension products added to the 
genotype reaction. Many samples required several runs with different dilution factor of 
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extension product before passing automatic data analysis, and each sample seemed to require 
different amount of extension template for acceptable signal peak heights.   
False-positive mutation was called for one SNP in codon 273 (CGT, c.817C>T) (Figure 26) in 
39 of 40 FFPE samples. The high rate of false-positives is unknown. No troubleshooting was 
conducted as our intent was to verify genotyped mutant alleles by Sanger sequencing. If 
primer stock solution for this allele was contaminated, this would not have been detected as 
new primer working solutions were made during the experiment. However, no signal peak 
height was observed in the blank containing all the necessary components for a successful 
amplification reaction if DNA had been present (Figure 27), and contamination is thus 
unlikely. Primer concentration was kept constant as recommended in the protocol. All false-
positives were verified as wild-type alleles by Sanger sequencing, and it will only be 
speculation as to the origin of these false-positives without having elucidated in detail.  
5.3.3 Ion Torrent PGMTM 
Ion Torrent sequencing was performed by another scientist during an ongoing evaluation trial 
of the PGMTM machine implemented at EpiGen. No details will be discussed regarding these 
experimental procedures, as we will only focus on the mutations detected in the samples (n = 
8) selected for Ion Torrent PGMTM sequencing. 
5.4 Mutations Detected in Each Method 
5.4.1 Sanger Sequencing 
Since we only focused on exon 5 through 9, the number of mutations (n = 18) that were 
detected in FFT samples (n = 37) are restricted. 
Although Sanger sequencing of FFPE samples was restricted to exon 8, an additional 3 
mutations were detected in these samples apart from the SNPs selected in the SNaPshot® 
assay. Otherwise, 5 of 6 mutations in FFPE samples were verified by Sanger sequencing.    
Deleted nucleotides were difficult to interpret with Sanger sequencing due to mixed peaks 3´ 
of the chromatogram. Tumors with suspected deletions were selectively chosen for Ion-
Torrent PGMTM sequencing.  
5.4.2 SNaPshot®  
FFPE samples revealed a total of 6 mutations (6/40 tumors) within 5 of 7 SNPs included in 
the SNaPshot® assay.  
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To portray a better representation of tissue specificity, FFT tumors were FFPE cast prior to 
SNaPshot® analysis. However, 2 of 3 samples failed automatic data analysis. All calculated 
scoring criteria (Supplementary Table G) were within acceptable range, and since these 
mutations were already confirmed by Sanger sequencing they were not optimized with 
additional runs. 
We did not attempt to validate assay sensitivity as this has been established by Dias-Santagata 
et al. (2010) as 3% input mutant DNA. Calculated amount of input mutant DNA material for 
all samples genotyped as a mutant (% MUT, Supplementary Table G) exceeds this limit.   
5.4.3 Ion Torrent PGMTM 
Ion Torrent results demonstrated that deleted nucleotides can be accurately determined 
through ion semiconductor sequencing. In addition, 1 missense mutation was detected in exon 
4 (Table 5), however, this mutation was not included for cancer analysis as our final analysis 
was restricted to exon 5 through 9. The respective sample was the one that failed PCR 
amplification for all primer pairs (Figure 18) according to Vu et al. (2008). In retrospect, after 
accurately determining the nucleotide composition of deletions, the inability to interpret the 
GHOHWHGQXFOHRWLGHVIURP6DQJHUVHTXHQFLQJPLJKWUHIOHFWWKHDXWKRU¶s inexperience. Once 
determined these nucleotides also became more prominent in the Sanger sequencing 
chromatograms.   
5.6 Cancer Analysis 
Different cancers show different mutational pattern, and some type of mutations show tissue-
specificity, like tandem mutations caused by UV-light and distinct mutations in lung cancer 
linked to cigarette smoke. Therefore, cancer analysis involves a detailed investigation of the 
specific mutant characteristics. From the cancer analysis conducted in this study, our results 
were in concordance with reported characteristics for TP53 mutations (Figure 29C and 30B). 
Most mutations were missense mutations that resulted in inactive protein, with a few 
nonsense mutations that result in early termination of a truncated protein. Only 1 mutation 
(codon 233, CAC) was reported to have no significant loss of activity (sup table x), and 
should be carefully reviewed before publication. However, this mutant was detected in both 
strands (Figure 20, C2) and was concluded to be a true mutation that was included in cancer 
analysis. Type I and type II CpG sites were frequently mutated (17/26) in proteins reported to 
be inactive. 
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Evaluation of chromatograms revealed several PCR artifacts portraying heterozygous 
mutations with double peaks (results not shown). Generation of UMD-p53 MUT-MAT_II 
table reported these mutations as previously never described (results not shown). Since most 
of these artifacts were observed in single strands from samples where both forward and 
reverse sequences were assembled, these mutations were concluded to be true PCR artifacts 
and excluded from any analysis. 
A detailed analysis of the mutational effect on protein function is important since incorrect 
mutant entries in the UMD-p53 database are estimated to account for 2-5% of all entries 
(Soussi & Beroud 2003). The curation of these mutations will continue to provide valuable 
information of the nature of TP53 function in carcinogenesis, and simple errors in TP53 
mutation reports should be avoided by all means. 
5.5 Survival Analysis 
In this study we have examined the overall survival outcome E\'XNHV¶VWDJHDQG TP53 
mutation status in 68 primary colorectal adenocarcinomas. Our results demonstrate that 
'XNHV¶VWDJH%LVpredictive of inferior survival with significantly worse prognosis in 'XNHV¶
stage C patients. No difference in survival is observed for TP53 wild-type patients opposed to 
TP53 mutant patients. However, 9 (wt (n = 4), mutant (n = 5) patients with missing 
clinicopathological data were excluded. 'XNHV¶VWDJHDQGTP53 status were the only 
parameters available for these patients, without any information of date of operation or 
registered follow-up date at any given time. By having to exclude 5 TP53 mutant patients 
'XNHV¶VWDJH%Q DQG&Q ) due to missing clinicopathological data, these results 
does not reflect the true survival outcome in the studied cohort.  
In addition, one patient with a mutation reported to have no loss in activity, were overlooked 
and included in the survival analysis table. This patient was alive at closing date and was 
treated as censored object for the Kaplan-Meier plots.  
5.3 Implementation of New Protocols 
This study was performed to evaluate the SNaPshot® fragment analysis assay, in contrast to 
Sanger sequencing, as a potential method to be introduced at Ahus for molecular profiling of 
FFPE material from CRC cases. Either of the performed protocols had previously been 
executed at EpiGen, and without an experienced conductor of these methods we faced many 
problems that could have been avoided with a detailed research regarding possible flaws in 
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protocol performance, and acquired more information about the instruments we used at 
EpiGen. Many aspects of this research have come about in a ³learning-by-doing´ manner. A 
valuable experience gained for prospective research work.  
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6 CONCLUSION  
We have found the SNaPshot® assay designed by Dias-Santagata et al. (2010) to be highly 
robust, sensitive and accurate, and ideal for use on FFPE derived DNA. This system can be 
used in any laboratory with a capillary DNA sequencer.  
Considering the nature of TP53 mutation spectra it is important to include all coding regions 
with exon/intron boundaries when conducting a mutation analysis of TP53. Although we 
confined our research to selected exons within the TP53 DNA binding domain, the 
SNaPshot® assay did not meet our expectations for our intended purpose of achieving new 
knowledge for colorectal cancer cases at Ahus.  
A signLILFDQWGLIIHUHQFHLQRYHUDOOVXUYLYDOZDVHVWDEOLVKHGIRU'XNHV¶VWDJH%SDWLHQWVEXW
not for TP53 wild-type patients. No mutations gave any indication of prognostic or predictive 
biomarkers 
The identification of new genetic markers is important for new drug development and to aid 
oncologists to the best suited treatment for their patients. We consider the SNaPshot® assay to 
have more relevance for detecting established, clinically proven molecular markers to stratify 
patients for best treatment outcome and survival predicament.  
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APPENDIX A: Supplementary Tables 
 
Supplementary Table A: Properties for TP53 amplification primer sequences according to Vu et al. 
(2008) and IARC (2010) protocols. 
Vu et al. (2008) 
Exon Amplification primer sequences PCR fragment length (Bp) 
2, 3 F - 5´-GGAGTGCTTGGGTTGTGGT-3´ 586 
R - 5´-CGGCAAGGGGGACTGTA-3´ 
4 F - 5´-GACTTCCTGAAAACAACG-3´ 593 
R - 5´-CACACATTAAGTGGGTAAAC-3´ 
5, 6 F - 5´-TTTCTTTGCTGCCGTCTTC-3´ 588 
R - 5´-TTGCACATCTCATGGGGTTA-3´ 
7 F - 5´-GACCATCCTGGCTAACGG-3´ 595 
R - 5´-CACAGGTTAAGAGGTCCCAAA-3´ 
8, 9 F - 5´-TTTGGGACCTCTTAACCTGT-3´ 733 
R - 5´-CAGGCAAAGTCATAGAACCAT-3´ 
10 F - 5´-CATGTTGCTTTTGTACCGTC-3´ 396 
R - 5´-GGCAAGAATGTGGTTATAGGA-3´ 
11 
 
F - 5´-AAGGGAAGATTACGAGACT- 3´ 500 
 R - 5´-TAAGCTGGTATGTCCTACTC-3´ 
Extension primer - Universal M13 sequences 
-21 M13 F - 5´-TGTAAAACGACGGCCAGT- 3´ NA 
-M13 REV R - 5´-CAGGAAACAGCTATGACC- 3´ NA 
2010 updated IARC protocol 
Amplification and extension primer sequences 
7 P-333 F - 5´-CTTGCCACAGGTCTCCCCAA-3´ 237 
P313 R - 5´-AGGGGTCAGAGGCAAGCAGA-3´ 
F = Forward, R = Reverse; Amplification primers are linked to universal M13 sequences in the 5` position 
 
 
Supplementary Table B: Properties for TP53 Sanger sequencing amplification and extension primer 
sequences according to Dias-Santagata et al., (2010). 
Primers Amplification and extension primer sequences Annealing Temp MgCl2 
TP53_ex5_ Seq_a1 5´-CTTGTGCCCTGACTTTCAAC-3´ 64ºC 40 nmol TP53_ex5_ Seq_a2 5´-ACCAGCCCTGTCGTCTCTC-3´ 
TP53_ex7_ Seq_a1 5´-TCATCTTGGGCCTGTGTTATC-3´ 58ºC 50 nmol TP53_ex7_ Seq_a2 5´-GAAATCGGTAAGAGGTGGGC -3´ 
TP53_ex8_ Seq_a1 5´-TTTCCTTACTGCCTCTTGCTTC-3´ 58ºC 50 nmol TP53_ex8_ Seq_a2 5´-GGAAAGGTGATAAAAGTGAATCTG -3´ 
 
 
 
 
 
 
 
 
II 
 
Supplementary Table C: SNPs targeted by the SNaPshot assay. 
Codon Nucleotide position CpG site 
175 c.524G Yes 
245 c.733G Yes 
248 c.742C Yes 
248 c.743G Yes 
273 c.817C Yes 
273 c.818G Yes 
306 c.916C Yes 
 
 
Supplementary Table D: Forward and reverse primer amount for SNaPshot®  analysis PCR reaction 
mix according to Dias-Santagata et al. (2010). 
Multiplex PCR primers Primer amount1 
Panel II - 742 
TP53_exon7_(a1+a2) 0.6 pmol 
Panel IV - 733 
TP53_exon7_(a1+a2) 0.6 pmol 
Panel V - 743/817 
TP53_exon7_(a1+a2) 0.6 pmol 
TP53_exon8_(a1+a2) 0.6 pmol 
Panel VI - 818 
TP53_exon8_(a1+a2) 1.2 pmol 
Panel VIII ± 524/916 
TP53_exon5_(a1+a2) 1.2 pmol 
TP53_exon8_(a1+a2) 0.6 pmol 
1´7KHYDOXHLQGLFDWHGUHSUHVHQWVWKHDPRXQWof eaFKIRUZDUGDQGUHYHUVHSULPHUDGGHGSHUȝORIPXOWLSOH[
3&5;SPRORIDDQG;SPRORID´ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III 
 
Supplementary Table E: Properties for TP53 SNaPshot® amplification- and extension primer 
sequences according to Dias-Santagata et al., (2010). 
Amplification 
primers Amplification primer sequences
 * 
TP53_exon 5_a1 5´-ACGTTGGATGCAAGCAGTCACAGCACATGA-3´ 
TP53_exon 5_a2 5´-ACGTTGGATGCTGCTCACCATCGCTATCTG-3´ 
TP53_exon 7_a1 5´-ACGTTGGATGTGGCTCTGACTGTACCACCA-3´ 
TP53_exon 7_a2 5´-ACGTTGGATGCCAGTGTGATGATGGTGAGG-3´ 
TP53_exon 8_a1 5´-ACGTTGGATGCTACTGGGACGGAACAGCTT-3´ 
TP53_exon 8_a2 5´-ACGTTGGATGGCTTCTTGTCCTGCTTGCTT-3´ 
Extension 
primers Extension primer sequences 
TP53_524_extF 5´-GACTGACTGACTGACTGACTGACTGACTGACTGACTGACTGA 
CTGACTGACTGACTGACTGACTGACTGACTGACCGGAGGTTGT G 
AGGC-3´ 
TP53_733_extR 5´-GACTGACTGACTGACTGACTGACTGACTGACTGACTGACTC C 
TCCGGTTCATGC-3´ 
TP53_742_extF 5´-ACTGACTGACTGACTGACTGACTGACTGACTGACTGACTGAC 
TGACTGACTGACTGGGGCGGCATGAAC-3´ 
TP53_743_extF 5´-CTGACTGACTGACTGACTGACTGACTGACTGACTGACTGACG 
GCGGCATGAACC-3´ 
TP53_817_extF 5´-CTGACTGACTGACTGACTGACTGACTGACTGACTGACTGACT 
GACTGACTGAGGAACAGCTTTGAGGTG-3´ 
TP53_818_extF 5´-ACTGACTGACTGACTGACTGACTGACTGACTGACTGACTGAC 
TGACTGACTGACTGACTGACTGACTGACTGAGAACAGCTTTGAG 
GTGC-3´ 
TP53_916_extR 5´-TGACTGACTGACTGACTGACTGACTGACTGACTGACTGACTG 
ACTGACTGACTGACTGACTGACTGACTGACTGACTGAGTCCTGCTGC
TTACCTC-3´ 
*10 nt long 5´- anchor tail (5´-ACGTTGGATG-3´) attached to all sequences; a1 = Forward, a2 = Reverse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV 
 
Supplementary Table F: Absorbance reading values of extracted DNA. 
Sample ID DNA ng/ul A260 A280 260/280 260/230 
CRC 88 58,70 1,174 0,594 1,98 0,84 
CRC 89 133,43 2,669 1,365 1,95 0,53 
CRC 90 110,60 2,212 1,297 1,71 0,31 
CRC 97 564,15 11,283 6,484 1,74 1,15 
CRC 104 87,94 1,759 0,912 1,93 0,46 
CRC 106 89,47 1,789 0,941 1,90 0,30 
CRC 107 132,52 2,650 1,525 1,74 0,52 
CRC 108 207,05 4,141 2,304 1,80 0,50 
CRC 112 72,99 1,460 0,743 1,96 1,71 
CRC 120 92,17 1,843 0,981 1,88 0,48 
CRC 124 156,36 3,127 1,754 1,78 0,45 
CRC 127 192,40 3,848 2,199 1,75 0,32 
CRC 134 43,08 0,862 0,441 1,96 1,92 
CRC 140 107,31 2,146 1,152 1,86 0,40 
CRC 143 79,14 1,583 0,790 2,00 1,22 
CRC 147 51,91 1,038 0,555 1,87 1,62 
CRC 164 102,97 2,059 1,044 1,97 0,81 
CRC 176 33,17 0,663 0,324 2,05 1,21 
CRC 200 104,33 2,087 1,059 1,97 0,75 
CRC 204 211,25 4,225 2,594 1,63 0,38 
CRC 207 106,06 2,121 1,054 2,01 1,28 
CRC 210 39,39 0,788 0,415 1,90 0,58 
CRC 211 129,15 2,583 1,296 1,99 1,74 
CRC 222 156,42 3,128 1,792 1,75 0,39 
CRC 232 94,94 1,899 0,952 2,00 1,39 
CRC 240 106,70 2,134 1,042 2,05 1,82 
CRC 253 88,20 1,764 0,886 1,99 2,01 
CRC 255 89,27 1,785 0,892 2,00 2,06 
CRC 269 32,10 0,642 0,325 1,98 1,21 
CRC 273 286,50 5,730 3,359 1,71 0,34 
CRC 280 85,95 1,719 0,945 1,82 0,39 
CRC 285 154,32 3,086 1,727 1,79 0,52 
CRC 290 46,29 0,926 0,472 1,96 1,26 
CRC 303 138,62 2,772 1,604 1,73 0,47 
CRC 304 38,08 0,762 0,406 1,88 1,51 
CRC 315 39,73 0,795 0,451 1,76 0,74 
CRC 345 38,75 0,775 0,396 1,96 1,46 
CRC-FFPE 108 470,37 9,407 4,610 2,04 2,05 
CRC-FFPE 204 199,54 3,991 2,049 1,95 1,66 
CRC-FFPE 280 367,31 7,346 3,619 2,03 2,10 
FFPE 1 291,60 5,832 2,849 2,05 0,75 
FFPE 2 49,23 0,985 0,445 2,21 0,26 
FFPE 3 101,40 2,028 1,027 1,97 0,47 
FFPE 4 94,84 1,897 0,901 2,11 0,38 
FFPE 5 146,10 2,923 1,430 2,04 0,81 
FFPE 6 267,70 5,355 2,599 2,06 0,95 
FFPE 7 354,80 7,096 3,463 2,05 1,24 
FFPE 8 227,80 4,557 2,209 2,06 0,94 
FFPE 9 285,20 5,704 2,790 2,04 1,13 
FFPE 10 89,08 1,782 0,839 2,12 0,59 
FFPE 11 371,80 7,435 3,594 2,07 0,93 
FFPE 12 258,70 5,174 2,472 2,09 1,15 
FFPE 13 141,90 2,837 1,365 2,08 0,74 
FFPE 14 191,30 3,827 1,847 2,07 0,53 
FFPE 15 166,30 3,325 1,617 2,06 0,53 
FFPE 16 266,40 5,328 2,531 2,11 0,71 
FFPE 17 67,67 1,353 0,646 2,09 0,32 
FFPE 18 131,20 2,624 1,330 1,97 0,65 
FFPE 19 94,82 1,896 0,979 1,94 0,61 
FFPE 20 103,90 2,079 1,003 2,07 0,55 
FFPE 21 40,50 0,810 0,395 2,05 0,37 
FFPE 22 263,60 5,273 2,503 2,11 0,78 
FFPE 23 108,50 2,171 1,003 2,16 0,31 
FFPE 24 152,90 3,058 1,488 2,06 0,77 
FFPE 25 187,10 3,743 1,839 2,03 0,52 
FFPE 26 189,10 3,783 1,860 2,03 0,80 
FFPE 27 293,10 5,861 2,873 2,04 1,04 
FFPE 28 246,90 4,938 2,387 2,07 0,94 
FFPE 29 224,20 4,484 2,135 2,10 0,82 
FFPE 30 252,20 5,045 2,378 2,12 0,63 
FFPE 31 221,70 4,434 2,053 2,16 1,05 
FFPE 32 197,40 3,948 1,874 2,11 0,99 
FFPE 33 253,30 5,065 2,409 2,10 0,74 
FFPE 34 281,42 5,628 2,747 2,05 1,06 
FFPE 35 244,77 4,895 2,449 2,00 1,08 
FFPE 36 126,10 2,522 1,201 2,10 0,84 
FFPE 37 181,18 3,624 1,750 2,07 0,92 
FFPE 38 258,03 5,161 2,527 2,04 0,82 
FFPE 39 139,69 2,794 1,417 1,97 0,34 
FFPE 40 190,34 3,807 1,911 1,99 0,82 
EtOH percipitated 
CRC 88 181,65 3,633 1,841 1,97 1,77 
CRC 89 280,96 5,619 2,796 2,01 2,00 
CRC 90 188,36 3,767 1,982 1,90 1,32 
CRC 97 373,70 7,473 3,833 1,95 1,89 
CRC 104 225,55 4,511 2,240 2,01 2,12 
CRC 106 180,38 3,608 1,806 2,00 2,06 
CRC 107 192,88 3,858 1,882 2,05 2,33 
CRC 108 70,10 1,402 0,703 1,99 1,87 
CRC 120 87,64 1,753 0,892 1,97 1,81 
CRC 124 84,37 1,687 0,864 1,95 1,83 
CRC 127 60,20 1,204 0,624 1,93 1,19 
CRC 140 87,56 1,751 0,880 1,99 2,15 
CRC 164 167,30 3,346 1,646 2,03 1,99 
CRC 200 151,16 3,023 1,507 2,01 2,05 
CRC 204 132,14 2,643 1,304 2,03 1,96 
CRC 210 54,76 1,095 0,555 1,97 1,91 
CRC 222 158,73 3,175 1,672 1,90 1,68 
CRC 232 90,26 1,805 0,876 2,06 1,70 
CRC 253 531,47 10,629 5,461 1,95 2,04 
CRC 273 237,70 4,754 2,536 1,87 1,10 
CRC 280 166,64 3,333 1,683 1,98 1,59 
CRC 285 158,49 3,170 1,656 1,91 1,62 
CRC 303 71,69 1,434 0,745 1,92 1,86 
CRC 315 34,42 0,688 0,375 1,83 1,82 
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Supplementary Table I: 'LVWULEXWLRQRIYLWDOVWDWXVIRU'XNHV¶VWDJH%DQG&SDWLHQWVQ 
68) with metastasis (w/ Met) and without metastasis (wo/ Met). 
'XNHV¶VWDJH NA Alive Dead 
    Colon cancer Other 
  w/ Met wo/Met w/ Met wo/Met w/ Met wo/ Met 
 wt mut wt mut wt mut wt mut wt mut wt mut wt mut 
B 3 2 1 0 19 10 0 0 0 0 0 0 3 1 
C 1 3 1 0 8 5 12 5 0 0 0 0 3 0 
NA; Not Applicable 
 
 
 
Supplementary Table J: Correlation between TP53 mutation status and clinicopathological 
data.  
 N % WT MUT r-value p-value 
TOT 68  N % N %   
Age         
<50 5 7.4 4 5.9 1 1.5 0,0664 0,5234 
>50 63 92.6 43 63.2 20 29.4   
Gender         
Female 42 61.8 30 44.1 12 17.6 0,0636 0,5225 
Male 26 38.2 17 25 9 13.2   
Tumor stage         
B 34 50 23 33.8 11 16.2 0,0318 0,5113 
C 34 50 24 35.3 10 14.7   
Metastasis         
Yes 19 28 14 20.6 5 7.4 -0,0615 0,4783 
No 49 72.1 33 48.5 16 23.5   
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